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Renal Proximal Tubular Cell Fibronectin Accumulation in response
Affected Carrierto Glucose is Polyol Pathway Dependent. K. Morrisey, R. Steadman,
RBP male femaleJ.D. Williams and A.O. Phillips, Institute of Nephrology, University of
mg/mmol Dents/ Dents/ NormalWales College of Medicine, Cardiff Royal Infirmary, Newport Road,
creatinine XRN XRN dRTA IH GN 16–68 yr.Cardiff. Thickening and reduplication of the tubular basement mem-
brane has been reported as an early event in diabetic nephropathy. In Median 17.8 0.30 0.027 0.0081 0.077 0.0079
the current study we have examined the polar requirements of proximal (10th–90th)
tubular cells for the D-glucose stimulated accumulation of fibronectin. centile (7.8–42) (0.13–3.1) (0.005–0.1) (0.004–0.017) (0.009–3.0) (0.004–0.011)
We also examined the mechanism by which glucose led to accumulation n 31 24 16 79 39 61
of fibronectin, with particular emphasis on the polyol pathway. Incuba-
tion of confluent monolayers of LLC-PK1 cells grown on tissue culture
inserts with 25 mM D-glucose on either their apical or basolateral
aspect, led to fibronectin accumulation in the basolateral compartment.
RBP was the optimal LMW protein to distinguish female CLCN5This reached statistical significance 24 h following apical addition of
carriers from normal (21/24 above normal reference limit) but RBPglucose (2.7 fold increase compared to 5 mM D-glucose, p 5 0.007, n 5
excretion by female carriers overlapped that of patients with dRTA,6), and 12 h after the basolateral addition of glucose (2.54 fold increase
IH and GN, as did RBP excretion by affected males and GN patients.compared to 5 mM D-glucose, p 5 0.02, n 5 6). The increase in
However, the combination of RBP and albumin uniquely identifiedfibronectin concentration in response to glucose was inhibited by the
the proteinuria of 52/55 patients with CLCN5 mutations. There wasaldose reductase inhibitor sorbinil. At a dose of 100lM sorbinil there
a striking correlation between RBP and albumin excretion in femalewas 59% inhibition of fibronectin accumulation in response to glucose,
CLCN5 carriers, R 5 0.933 after logarithmic transformation, sug-48 h after the addition of the inhibitor (4.76 6 1.4 vs 11.53 6 1.41,
gesting a shared tubular transport mechanism. An RBP level abovemean 6 SD, p 5 0.01, n 5 3). Exposure of cells to glucose at either
the upper adult reference range (0.017) and albumin level ,(10 3their apical or basolateral aspect lead to accumulation of intracellular
RBP)12 identified all patients with the LMW proteinuria of CLCN5glucose and polyol pathway activation, as assessed by sorbitol accumu-
mutations; this is therefore a possible quantitative definition of tubularlation. Accumulation of intracellular glucose and hence subsequent
proteinuria. Using this definition, most patients with Chinese Herbspolyol pathway activation occurred independently of transport of glu-
Nephropathy, (a complex interstitial nephritis with elevated urinarycose by either apical sodium linked glucose transporter (SLGT) or
RBP and albumin levels), had tubular proteinuria.basolateral GLUT 1. The data demonstrate that fibronectin generation
in response to glucose was non-polar in terms application of glucose,
but polar in terms of fibronectin accumulation. Furthermore modula- Increased apoptosis in acute renal transplant rejection is not associated
tion of fibronectin was mediated by polyol pathway activation, and with altered fas and fas-ligand expression. C.J. Porter, J.E. Ronan*, I.D.
more specifically related to the metabolism of sorbitol to fructose. Ansell* M. Shehata and M.J.D. Cassidy, Renal Unit and Histopatholgy*,
Nottingham City Hospital NHS Trust, Nottingham, U.K. Preliminary
reports suggest that cell deletion by unscheduled apoptosis is increasedLow Molecular Weight (‘Tubular’) Proteinuria in Patients with Muta- in renal transplant biopsies from patients with acute rejection, but the
tions of the CLCN5 Renal Chloride Channel Gene. A.G.W. Norden1, mechanisms responsible have been obscure. We aimed to examine
J. Asplin2, M.M. Deschodt-Lanckman3, M. Lapsley1, J.L. Nortier3, S.J. the possible role of fas-ligand (fas-l), a TNF-cytokine which triggers
Scheinman4, R.J. Unwin5 and O.M. Wrong5, 1Department of Chemical apoptosis in cells expressing the fas death receptor, since both fas and
Pathology, Chase Farm Hospital, The Ridgeway, Enfield EN2 8JL, fas-l can be expressed by infiltrating leukocytes and resident renal
Middlesex, England, 2Section of Nephrology, University of Chicago, cells. We employed well established histological techniques to study 19
IL, U.S.A., 3Laboratoire Pluridisciplinaire de Recherche Experimentale acute renal transplants biopsies from 14 patients in whom histologically
Biomedicale, Brussels, Belgium, 4Department of Medicine, SUNY normal preimplantation biopsies were available. Apoptotic cells, de-
Health Science Centre, Syracuse, N.Y. U.S.A.,5 Centre for Nephrology, tected by nick end labelling of cleaved DNA using the Apotag peroxi-
University College London Medical School, London, England. Identi- dase technique, could not be observed in 10 high power fields (340) in
fication of tubular proteinuria appears to be the most consistent screen- all pre-implantation biopsies. However in 7 cases with definite rejection
ing test for the X-linked renal syndromes including Dent’s Disease (Banff score 4/1 or 4/2) there were 11 6 3 (mean 6 SE, p , 0.0006
and X-linked recessive nephrolithiasis (XRN) caused by mutations of Kruskal Wallis) apoptotic cells per hpf, the apoptotic cells were pre-
the voltage-gated chloride channel gene CLCN5. The prevalence of dominantly interstitial but in 2 cases tubular cells also labelled. Further-
tubular proteinuria in patients with CLCN5 mutations compared to more, as expected, when compared with preimplantation material,
those with the overlapping syndromes of distal renal tubular acidosis biopsies with rejection exhibited increased infiltration with CD43 posi-
(dRTA), idiopathic hypercalciuria (IH) and also patients with glomeru- tive T-cells but no increase in CD68 positive monocytes. Fas and Fas-
lonephritis, in whom low molecular weight (LMW) proteinuria is com- ligand expression appeared as membrane staining, although fas-ligand
mon, is unknown. The LMW proteins retinol-binding protein (RBP), also appeared intracellularly. In the 7 cases of rejection fas and fas-l
b-2 microglobulin, a1-microglobulin and albumin were measured in expression was assessed by semi-quantitative immunohistochemistry
the urine of these groups of patients. RBP levels in random urine on a scale of 0–3 (i.e. 0 5 no staining, 1 5 faint staining, 2 5 definite
staining, 3 5 strong staining) as shown:specimens were as follows:
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and at least one other member with either biopsy confirmed FSGS or
Score ESRF. We have observed a vertical mode of inheritance consistent
with autosomal dominant (AD) inheritance in 26 families. Familial0 or 1 2 or 3
aggregation in the remaining 34 pedigrees is consistent with autosomal
Tubular epithelium recessive (AR) inheritance or AD with reduced penetrance. Males
fas pre 6 1 and females were affected equally. The mean age at presentation was
fas post 3 4 higher in the AD cases (32.5 6 14.6 years) than in the AR cases (20.1 6
fas-l pre 4 3 5.6 yr., p 5 0.0001). AR cases had more proteinuria at presentation
fas-l post 6 1 (7.0 6 1.56 g/24 hrs) than AD cases (3.8 6 3.4 g/24 hrs, p 5 0.002).
Glomerular One half of the patients had progressed to ESRF by the age of 50
fas pre 7 0 years. Young age, renal impairment, and heavy proteinuria at presenta-
fas post 7 0 tion were independently associated with poor renal survival. Forty one
fas-l pre 7 0 patients had a successful renal transplant with a 10-year graft survival
fas-l post 7 0 rate of 62%. One patient has developed clinical and biopsy evidence
Interstitial of recurrence of FSGS in the allograft. Five large pedigrees exhibiting
fas pre 7 0 apparent AD inheritance with blood samples on 34 affected individuals
fas post 6 1 were investigated for four candidate regions. These regions included
fas-l pre 7 0 the locus for Familial steroid resistant nephrotic syndrome, PAX2
fas-l post 5 2 for which the phenotypic spectrum associated with mutations include
glomerular abnormalities consistent with FSGS pattern and CMT1A
and CMT1B, as some families with FSGS also have peripheral neuropa-
thy. All four regions were excluded using the standard 22 LOD criteria.
These data confirm the presence of a non-Alport form of hereditaryWe conclude that there is no significant increase in either fas or fas-l
nephritis that has a morphological pattern of FSGS.expression by tubular epithelial cells or (unspecified) interstitial cells
in 7 cases of acute renal transplant rejection where preimplantation
material was available, despite significant increases in interstitial apo-
Diastolic blood pressure is important in the progression of chronicptosis and T-cell infiltration.
renal failure (CRF): a retrospective review. C.J. Deighan, K. Simpson
and J.M. Boulton-Jones, Renal Unit, Glasgow Royal Infirmary, Glas-
gow. Proteinuria and renal diagnosis independently predict outcomeEffects of hypoxia on vascular patterning in the embryonic kidney.
in CRF, however the relative importance of good blood pressure (BP)A.S. Woolf and S. Loughna, Nephrourology Unit, Institute of Child
control in preventing progression of CRF has recently been questioned.Health, London WC1N 1EH. The mode of development of the renal
We analysed retrospectively the effect of systolic (SBP) and diastolicvasculature is not fully understood. Tie1 is an orphan receptor tyrosine
BP (DBP), proteinuria, cholesterol, sex and diagnosis on rate of pro-kinase expressed by the endothelial lineage. Tie1 null-mutant mice lack
gression of 484 patients with CRF. Patients required .6 months follow-embryonic blood vessel integrity and studies of Tielcz/Tielczn- chimeras
up, 4 BP and creatinine measurements and progressive CRF, definedsuggest a critical role for the gene in metanephric vessel formation.
as a 10% decrease in estimated creatinine clearance (calculated usingUsing Tie1/LacZ mice, which develop normally but express a
the Cockcroft and Gault formula) to ,50 ml/min/1.73m2. The main∃-galactosidase transgene in both differentiating and mature kidney
diagnostic groups were glomerulonephritis (99 patients), interstitialendothelia, we demonstrated that endothelial precursors present on
disease (111), polycystic kidney disease—APKD (58) and diabetic ne-the day of inception of the metanephros differentiated into glomerular
phropathy (75). Stepwise regression and multivariate analysis werecapillaries and arterioles after rudiments were transplanted into and
used to identify relative contribution to variability in rate of progressiongrew within the neonatal nephrogenic cortex of wild-type mice
of CRF (DECC).(Loughna et al. Angiogenesis 1997;1:84–101). This genetic analysis es-
tablishes an endogenous origin for glomerular endothelia. We ex-
ploited organ culture to further explore endothelial development using
embryonic day 13 Tie1/LacZ metanephric explants, a stage when con- Median Interquartile range
densates and S-shaped bodies (nephron precursors) are present and
DECC (ml/min /mth) 20.32 20.21:20.78surrounded by leashes of reporter gene-expressing cells, but glomeruli
SBP (mm Hg) 149 137:161have not yet formed. In serum-free culture in 5% CO2 and air (21%
DBP (mm Hg) 83 77:89O2), avascular glomeruli developed but existing vessels regressed, with Proteinuria (g/24 hrs) 1.8 0.8:3.4little transgene expression by the 4th day. In contrast, in serum-free
Cholesterol (mmol /l) 6.1 5.0:7.1culture in 5% CO and 3% O2, intense Tie1/LacZ expression was noted
in the explant in discrete structures located between tubules and often
as large as tubules themselves. These masses of cells sometimes con-
All Men Womentained poorly-developed complexes of lumens and resembled tumour-
like hemangiomas. Although glomeruli developed in hypoxia, they Univ. Multiv. Univ. Multiv. Univ. Multiv.
were devoid of morphological capillary loops and transgene expression r2 r2 r2 r2 r2 r2
even on prolonged culture to 7 days. The addition of increasing concen-
SBP 3.7%a 0.3% 4.0b 0% 3.9%b 0.8%trations (0.5–5.0%) of fetal calf serum prevented the formation of
DBP 8.9%a 5.9%a 11.9%a 6.9%a 5.4%a 4.7%bthese endothelial masses. We conclude that endothelial survival and
Proteinuria 14.8%a 7.9%a 20.5%a 12.1%a 9.5%a 4.2%cgrowth in organ culture is inhibited by oxygen and (unknown) serum
Cholesterol 3.1%a 1.1%d 7.3%a 0.9% 2.1%d 0.5%factors. Although hypoxia is permissive for metanephric endothelia,
Diagnosis — 1.0%d — 0.6% — 2.4%dvascular patterning is highly abnormal in this milieu.
Abbreviations are: Univ., univariate; Multi., multivariate.
a p , 0.001; b p , 0.002; c p , 0.01; d p , 0.05
Spectrum of Disease in Familial Focal and Segmental Glomeruloscle-
rosis (FFSGS). P.J. Conlon1,2, M. Winn2 and D. Howell2, on behalf of
Proteinuria contributed most to variability of DECC, however DBPthe International Collaborative Group for the Study of Familial FSGS,
was more important in women. Neither sex nor SBP was significant.1Beaumont Hospital, Dublin 9, Ireland and 2Duke University North
Proteinuria and DBP combined, accounted for 13.8% of variability ofCarolina. FSGS is the cause of end stage renal failure (ESRF) in 5%
DECC in all patients. In the 4 main diagnostic groups, DBP was the onlyof adults and 20% of children. It is generally sporadic in nature. We
contributor to variability of DECC in APKD and interstitial diseasehave identified 60 families involving 190 individuals with familial FSGS.
Each family had at least one member with biopsy confirmed FSGS (13.2%d & 6.2%d), whereas both proteinuria and DBP contributed in
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glomerulonephritis (13.2%a & 9.9%a). Proteinuria and cholesterol were (nmol/l), and % figures are proportion of patients in hypogonadal
categories by modality.significant in diabetic nephropathy (11.7%c & 6.8%d). We conclude
that DBP is an independent contributor to the rate of progression of
CRF, is as important as proteinuria and contributes more to DECC
than diagnosis. Low
Hemodialysis CAPD Transplants clearance
n 5 23 n 5 12 n 5 14 n 5 42
Urinary neutral endopeptidase activity: a possible marker for renal
Mean age years 56.5 59.5 39.5a 61.1damage following cardiac surgery. H. Mistry, 1P.M. Sutton, 2M.F. Wal-
Testosteroneter, 1M.S. Sumeray, 2R. Woolfson and 2R.J. Unwin, Department of Physi-
(mean6sd) 10.2 63.8 11.6 66.0 14.564.9 11.8 65.7ology, 1Department of Academic Cardiology, 2Centre for Nephrology,
Low testosterone 47% 33% 14% 36%Department of Medicine, University College London Medical School,
Low-normal 43% 50% 36% 36%London W1N 8AA. The brush border of the renal proximal tubule
is rich in neutral endopeptidase (NEP). Pathological changes in the a P , 0.05
proximal tubule are associated with shedding of the brush border
membrane and increased appearance of NEP in the urine. The aim
of this project was to assess the clinical usefulness of urinary NEP as No significant changes were seen in SHBG or gonadotrophin concen-
a marker of renal tubular injury in patients undergoing revascularisa- trations. Only 25% of all patients had normal testosterone; these pa-
tients were younger (mean 6 SEM; 48.7 6 3.3 years, P , 0.01) thantion for coronary artery disease. Patients either underwent percutane-
patients with low or low-normal testosterone levels (57.6 6 3.3 andous transluminal coronary angioplasty (PTCA) or coronary artery by-
60.5 6 2.9 years, respectively). These findings have several importantpass grafting (CABG). The former involves the use of a potentially
implications. Over a third of our patients with renal failure, evennephrotoxic radiocontrast and the latter requires cardiopulmonary by-
in the pre-dialysis phase, can be considered to have this potentiallypass, a technique which may result in inadequate renal perfusion. Urine
reversible risk factor for osteoporosis. They might benefit from testos-from PTCA patients (n 5 8) was collected one hour before and two
terone replacement which has been shown to increase bone mineralhours post angioplasty and assessed for NEP activity. The urine from
density in both hypogonadal and eugonadal men, and such treatmentCABG patients (n 5 8) was collected on the day before surgery,
can also improve sexual dysfunction. Transplant patients, despite oftenand 4 hours, 1 and 3 days postoperatively. Urinary NEP activity was
being younger, may also be hypogonadal and this is an added riskmeasured and assayed for both NEP activity and alkaline phosphatase
factor for osteoporosis in a patient group also likely to receive highactivity (a recognised marker for tubular injury) — see table:
dose corticosteroids. We intend to study the correlation between bone
mineral density (using DEXA) and gonadal status in these patients,
before investigating the effects of testosterone therapy upon this andAlkaline sexual dysfunction.phosphatase
NEP activity activity
Reduced serum high-density lipoprotein: a cause of proteinuria rather(mean6sem)
than a consequence? C. Brunton1, Z. Varghese, and J.F. Moorhead,Procedure (arbitrary units/mOsm)
Renal Unit, Aberdeen Royal Infirmary1 and Dept. of Nephrology and
PTCA pre-op 0.6560.09 — Transplantation, Royal Free Hospital, London. Lipid peroxidation
PTCA post-op 0.7260.10 — (LPO) has been implicated in tissue injury in experimental models of
CABG pre-op 0.6061.50 7.461.4 nephritis, and there is evidence that oxidation of low density lipoprotein
CABG 4 hr post-op 1.56 60.66 15.065.3 (LDL) by endothelial and mesangial cells amplifies glomerular injury
CABG 1 day post-op 1.09 60.19 10.263.4 and may aggravate proteinuria. Lipid peroxidation can be assessed in
CABG 3 days post-op 0.96 60.23 13.565.6 vitro using the diene conjugation assay which is a surrogate for the
susceptibility of LDL to oxidation; known as the lag time. Factors
influencing the lag time include amount of pre-existing lipid hydroper-
Urinary NEP concentration rose following PTCA but not significantly oxides and serum anti-oxidants. High density lipoprotein (HDL) does
(P 5 0.18). CABG surgery resulted in a significant increase in urinary not contain endogenous antioxidants but protects against LPO by
NEP activity (P , 0.004). This rise correlated with urinary alkaline preferentially carrying lipid hydroperoxides (,85%), and facilitating
phosphatase activity (r2 5 0.45, P , 0.0001). Many cardiac procedures their removal by the liver. Serum levels of HDL, which is mainly
are followed by, or result in, acute renal dysfunction. It is possible that composed of apolipoprotein A1, are frequently low in the nephrotic
the earlier detection and quantification of renal proximal tubular injury syndrome (NS) and could potentially increase LPO in the glomerulus
will allow more rapid identification of patients at greatest risk and and indirectly proteinuria. In order to test this hypothesis a group
prophylactic intervention. of 20 nephrotic patients with biopsy proven glomerular disease and
proteinuria of .3 g/24 h were studied. Lipid profile, antioxidants, GFR
and urinary protein (g/24 hrs) were measured and lag time analysed
Prevalence of biochemical hypogonadism in male renal replacement using diene conjugation.
therapy (RRT) and low clearance (pre-dialysis) patients. F. Al Baaj,
P.A. Haynes1, G. McKinnon2, D.J. O’Donoghue, S. Waldek, P.A. Kalra,
Depts of Renal Medicine and Endocrine Biochemistry2, Hope Hospital, Corr. coeff.
Salford and Rheumatology, Royal Oldham Hospital1. Male hypogo- Correlation rs P value
nadism may be secondary to renal failure, and it is thought to contribute
HDL mmol /l vs. urinary protein g/24 hrs 20.464 ,0.05towards the sexual dysfunction and osteoporosis experienced by RRT
HDL mmol /l vs. urinary proteinpatients. However, few systematic studies have been performed in
corrected for GFR lg/ml 20.550 ,0.02these patient groups. We performed a cross-sectional analysis of go-
Serum ApoA1 g/l vs. lag time minutes 20.554 ,0.02nadal status in 91 male patients (42 low clearance, 49 RRT), mean
Urinary protein g/24 hrs vs. lag time minutes 20.456 ,0.05age 56.3 years, on our programme. Non-fasting plasma was analysed
for testosterone, sex hormone binding globulin (SHBG), FSH and LH.
Testosterone concentrations were classified as Normal (.14 nmol/l),
Low-normal (10–14 nmol/l) or Low (,10 nmol/l). 32 (35.2%) patients The results show that low serum HDL (as assessed by serum apoA1
had significantly low testosterone concentations, and another 36 level) and increased proteinuria were associated with shorter lag times.
(39.6%) low-normal. The table shows the relationship of gonadal status This implies that protection from LPO is reduced in patients with
proteinuria, and may be related to the lower HDL levels incurred.to modality of RRT. Testosterone concentrations are mean 6 SD
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Reducing lipid peroxidation may therefore prove to be more beneficial Severity of proximal renal artery lesions does not predict renal dysfunc-
tion in patients with atherosclerotic renovascular disease (ARVD). M.in decreasing proteinuria than lowering the LDL levels.
Suresh, P. Laboi, H. Mamtora1, P.A. Kalra, Depts. of Renal Medicine
and Radiology1, Hope Hospital, Salford. ARVD is a common cause
of renal disease but outcomes seem to vary, with some patients havingIndividual kidney function before and after renal angioplasty. C.K.T.
Farmer, J. Reidy1, P.A. Kalra2, G.J.R. Cook3 and J. Scoble, Department severe structural lesions and well-preserved renal function, and yet
others with lesser lesions may still progress to end-stage renal failureof Renal Medicine, Guy’s Hospital, Department of Radiology Guy’s
Hospital1, Department of Renal Medicine, Hope Hospital, Salford2, (ESRF). Although radiological intervention with renal angioplasty or
stenting may prevent progression to ESRF in some patients, this is notDepartment of Nuclear Medicine, Guy’s Hospital3. Angioplasty of the
renal artery has been used to attempt to prevent end stage renal disease. always predictable. The angiographic findings of 62 patients with ARVD
However the surrogate measures of renal function have been flawed currently on the local Renovascular Disease Database were examined
as measurements of overall function have been used rather than the in the context of their renal function assessed at the time of angiogra-
function in the angioplastied kidney. We have applied a novel tech- phy. The severity of the renovascular lesions was arbitrarily represented
nique of measurement of kidney function to examine the individual by residual proximal renal artery lumen patency. For example: Bilateral
function in each kidney before and after angioplasty is performed. normal 5 2.0; unilateral 50% renal artery stenosis (RAS) 5 1.5; unilat-
We followed up 16 patients with our method of assessing single kidney eral renal artery occlusion (RAO) or bilateral 50% RAS 5 1.0; RAO
glomerular filtration rate (SKGFR). The SKGFR was measured with 70% RAS 5 0.3. Diabetes was present in 7 patients, who were
using synchronous 51Chromium ethylene diaminotetraacetic acid (51Cr- excluded. Mean (6SD) age of the remaining 55 patients was 66.2 6 9.9
EDTA) clearance and 99mTechnectium dimercaptosuccinic acid (99Tc- years and male (n 5 33) to female ratio was 1.5:1.
DMSA) scanning. The combination of the two investigations per-
formed synchronously gives an indication of the glomerular filtration
rate provided by each kidney. We performed a total of 72 single kidney Residual proximal renal artery lumen patency
glomerular filtration rates in 16 patients, the mean age of our patient (maximum 5 2.0) (mean 6SEM)
group was 70.8 years (59.7–88.2 years), the mean time between each
.1.5 1.0–1.4 0.5–0.9 ,0.5SKGFR was 6.47 months (1.14–15.51). We found there was no signifi-
n 5 9 n 5 23 m 5 13 n 5 9cant difference between mean SKGFR pre and post angioplasty group
(pre 23.05 post 24.20 ml/min/1.73m2); the results were similar for normal Creatinine clearancerenal arteries. We suggest that angioplasty does not improve renal ml/min 34.866.7 30.7 64.3 32.3 67.2 37.4 67.0function in the angioplastied kidney in the short term. We do however 24 hour proteinuriaknow that the rate of progression of severely stenosed renal arteries gm 0.4460.23 0.92 60.25 0.94 60.38 0.54 60.19to occlusion is approximately 5% per. The role of renal angioplasty
may be to prevent progression to occlusion which may occur painlessly.
All comparisons were non-significant. Renal function was completely
independent of the severity of proximal ARVD. This was further
illustrated by the finding that 4 (44%) patients with residual patency
. 1.5 had creatinine clearances ,20 ml/min, whereas 3 (33%) patients
with residual patency ,0.5 had creatinine clearances .50 ml/min. The
severity of accompanying renal parenchymal disease, due to atheroscle-
rotic nephropathy (intra-renal atheroma, ischaemia and cholesterol
athero-emboli), is also a major determinant of renal function in patients
with ARVD, and this should be considered separate to the proximal
vascular disease. Further, if angioplasty or stenting is contemplated in
ARVD then measurement of individual kidney function by single
kidney GFR may help select the appropriate kidney for intervention, so
increasing the likelihood of favourable long-term functional outcome.
Progression of Renal Artery Stenosis in Patients Undergoing Cardiac
Catheterization. 1P.J. Conlon, 2J. Crowley, 1,2Beaumont Hospital, Dub-
lin, Ireland and 1Duke University Medical Center, North Carolina, USA.
Renal vascular disease is a potentially reversible form of renal failure.
To date there has been a dearth of data pertaining to the natural
history of renal vascular disease. In order to further study the natural
history of atherosclerotic renal vascular disease we have had a policy
of performing an abdominal aortogram on most patients who undergo
coronary angiography at DUMC. 1,189 patients from a total of 14,259
who had undergone abdominal aortography were included in this anal-
ysis. Each patient had at least two abdominal aortograms separated
by a period of 6 month. The degree of renal artery stenosis was assessed
at baseline and follow-up. The mean age of subjects was 60 6 10 years,
60% were male. The mean time between cardiac catheterizations was
2.6 6 1.6 years. At baseline, bilateral normal renal arteries were identi-
fied in 1,089 patients (91.5%), insignificant (,50%) stenosis in 62
patients (5.2%), and significant stenosis ($50) stenosis in 38 patients
(3.2%). By multivariate logistic regression, age, female sex and pres-
ence of peripheral arterial disease were independent predictors of
significant renal arterial disease. Disease progression (Defined as in-
crease in percent stenosis of $50%), between baseline and follow-
up was observed in 133 patients (11.1%). Independent multivariate
predictors of disease progression were female sex, increased age, num-
ber of coronary arteries with significant disease at baseline and time
between baseline and follow-up. Serum creatinine was significantly
higher in patients who demonstrated $75% stenosis in one or more
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vessel (mean serum Cr 141 6 114 umol/L) compared to those with basis for tailoring or withdrawing immunosuppression. In this study,
a limiting dilution assay was used to measure the frequencies of in-insignificant disease (mean Cr 97 6 44 umol/L, p 5 0.01).
terleukin-2-producing helper T cells with direct allospecificity for donor
compared to third party stimulator cells in renal transplant recipients.
Donor-specific helper T cell precursor frequencies were low, comparedWithdrawal of steroid immunosuppression in functioning renal allo-
graft recipients. G. Jones, R. McGonigle and P. Rowe, Dept. Renal with third-party frequencies in 5/11 recipients of long-term live-related
kidney transplants with stable function. In addition, 21 patients wereMedicine, Derriford Hospital, Plymouth. The European Collaborative
Transplant Study suggested that 5 year graft survival is best amongst analysed on the day of, and weeks or months later. In eight of these
patients a striking fall in donor-spefic frequency was observed. Further-patients receiving steroid free immunosuppression. We withdrew pred-
nisolone successfully after 12 months in 85 of 90 patients from 173 more, in eight of nine patients in whom a high anti-donor frequency
was sustained, addition of anti-CD4 monoclonal antibody resulted in areceiving triple immunosuppression. Median follow up was 17.1 months
(range 4.6–271.2). Eleven patients (12.9%) restarted steroids at a me- significant reduction in donor-specific, but not third-party, frequencies
suggesting that high affinity anti-donor T cells had been inactivateddian of 189 (range 70–520) days. Six patients (7%) experienced acute
rejection at a median of 108.5 (range 19–547) days. Four patients in these individuals. These data indicate that donor-specific T cell
hyporesponsiveness occurs spontaneously in most renal transplant re-(4.7%) developed chronic rejection. Two grafts (2.3%) were lost, both
from chronic rejection; at 203 and 336 days. Mean arterial blood pres- cipients. Given that chronic graft rejection occurs in the majority of
patients, and that this may be driven by T cells with indirect allospeci-sure was no different before or 12 months after steroid withdrawal
(101.7 vs. 101.2; p 5 0.84), with no reduction in the use of antihyperten- ficity, it will be important to quantitate anti-donor indirect allore-
sponses, before concluding that tolerance has occurred.sive agents (66.7 % vs. 65.2%). There was no significant fall in weight
(mean 72 Kg vs. 71.1 Kg six months post; p 5 0.25). The rate of decline
in renal function, as recorded by the slope of reciprocal creatinine
against time, was significantly worse after withdrawal (pre 5.14 3 1027, Class II matching is the major correlate of kidney allograft rejection
in the first week post-transplantation. A.G. McLean, E. Psimenou, B.post 27.9 3 1027; p 5 0.0065). Serum creatinine increased from 138.4,
to 150.5 at six months (p 5 0.010) and 161.1 at twelve months (p 5 Subel, Y. Jones, O. N. Fernando and P. Sweny, Centre for Nephrology,
Royal Free Hospital, Pond Street, London NW3 2QG. In the course0.029). This analysis shows an initial increase in creatinine and a small
increase in the rate of loss of renal function after steroid withdrawal. of a randomised, controlled study of the effect of per-operative bolus
Methyl-Prednisolone (15 mg/kg given at the time of release of vascularWhether this will result in a long-term reduction in graft survival and
function has yet to be demonstrated. The rate of acute rejection (7%) clamps) on rejection and other post-transplant complications, we have
studied the pre- and post- transplant factors associated with the onsetwas much smaller in this study compared with previous reports but
the anticipated benefits on body weight and blood pressure control of biopsy-proven acute cellular rejection within the first seven days
post transplantation. Patients were randomised to receive pulsed ste-were not seen. In the light of these findings a policy of non selective
withdrawal of steroid immunosuppression requires reconsideration. roid (MP group) in addition to standard triple therapy (Prednisolone,
Azathioprine, and Cyclosporin) or triple therapy alone (NoMP group)
within three stratification groups: first cadaver transplant (n 5 12 MP/
14 NoMP), second or subsequent cadaver transplant (N 5 5 MP/5Tacrolimus as a first-line treatment for steroid-resistant acute rejection.
M.S. MacGregor, R.S.C. Rodger, M.A. Watson, M.A. McMillan, BJR NoMP), and live related transplant (n 5 8 MP/6 NoMP). Patients given
ten days prophylactic ATG after second or subsequent transplantsJunor and J.D. Briggs, Renal Unit, Western Infirmary, Glasgow, G11
6NT, Scotland. Tacrolimus is an effective treatment for acute rejection were not included in analysis of rejection during the first week. Factors
analysed were: Pulsed steroid vs No pulsed steroid (MP vs NoMP),resistant to anti-lymphocyte antibodies (ALA), reversing 79% of such
episodes. However, this approach still exposes patients to the risks Mean Cyclosporin levels greater or less than 150 ng/ml assayed by
HPLC (CyA High vs CyA Low), Live related vs cadaver grafts (LRDassociated with ALA. We investigated the efficacy of tacrolimus as a
vs Cadaver), 0 or 1 Class I mismatches vs greater than 1 Class Ifirst-line treatment for steroid-resistant acute rejection in unselected
mismatches (0/1 vs .1 Class I MM), 0, 1 or 2 Class I mismatches vsrenal allograft recipients. 149 patients received grafts between Novem-
greater than 2 Class I mismatches (0/1/2 vs .2 Class I MM), and 0ber 1995 and December 1997 and were maintained on cyclosporin-
DR vs 1 or 2 DR mismatches (0 DR MM vs 1/2 DR MM).based regimens. Sixteen patients (13 male), aged 35 (16–60) years,
developed acute rejection 19 6 13 days after transplantation, which
became steroid-resistant, defined as biopsy-proven rejection prog-
ressing despite high-dose steroids, or recurring within 14 days of com- Risk of rejection
pletion of the steroid course. Tacrolimus was started 6.5 (3–23) days Risk factors within 1 week x2 p
after onset of rejection at 0.2 mg/kg/day and adjusted to maintain
0 DR MM vs. 1/2 DR MM 10% vs. 44% 5.81 0/016whole blood trough levels of 10–15 ng/ml. Fourteen patients (87.5%)
CyA High vs. CyA Low 20% vs. 41% 0.41 NShave a functioning graft at latest follow-up of 12.9 (1.1–22.9) months.
MP vs. NoMP 26% vs. 35% 0.4 NSBy 3 months, serum creatinine had fallen to 49 6 23% of the value
LRD vs. Cadaver 28% vs. 32% 0.36 NSat initiation of tacrolimus therapy (447 6 201 mmol/l) and to 104 6 42%
0/1 vs. .1 Class I MM 29% vs. 36% 0.2 NSof the lowest ever value (227 6 133 mmol/l). Mean serum creatinine fell
0/1/2 vs. .2 Class I MM 31% vs. 31% 0 NSto 288 6 173, 190 6 89 and 181 6 86 mmol/l at 1, 3 and 6 months
respectively, and was 181 6 73 mmol/l at latest follow-up. One patient
did not respond to tacrolimus and lost their graft. One patient died
suddenly at home with improving graft function, and one each devel- The presence of any mismatches at DR loci (defined by serology in
oped pneumonia and CMV disease. Our experience suggests that this study, but confirmed by PCR genotyping in the majority of patients)
was therefore substantially the strongest predictor of acute rejectiontacrolimus is an effective first-line agent for the reversal of steroid-
resistant rejection with an acceptable safety profile. Early use of tacroli- within 7 days. This implies that the immune mechanisms responding
to Class II mismatches operate over a shorter time-scale than thosemus instead of, rather than after ALA, may reduce the risks of infection
and neoplasia. responding to Class I mismatches alone.
L-Arginine transport and metabolism in blood cells in Renal and HeartRenal transplants induce donor-specific hyporesponsiveness. P. Mason,
L. Weng1 and R. Lechler1, Oxford Renal Unit, Churchill Hospital, Ox- failure: Is there NO. answer? A.C. Mendes Ribeiro1,4, N. Ashman3,
T.M.C. Brunini1,4, H. Hanssen1, N.B. Roberts2, M. Yaqoob3, J.C. Ellory1ford and 1Dept. Immunology, Imperial College School of Medicine,
Hammersmith Hospital, London. Prolonged administration of immu- and G.E. Mann4, 1University Laboratory of Physiology, Oxford OX1
3PT and 2Department of Clinical Chemistry, Royal Liverpool Hospital,nosuprressive drugs is complicated by substantial morbidity and mor-
tality due to opportunistic infections and malignancy. Identification of Liverpool L7 8XP, 3Renal Unit, London Royal Hospital, London E1
1BB and 4Vascular Biology Research Centre, King’s College Londonpatients in whom donor-specific tolerance occurs could provide the
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W8 7AH, U.K. Chronic renal and heart failure is associated with an acid-induced protein wasting relative to that in controls with 0.4 mM
Leu. PD was measured from release of 14C-Phe from labelled cells. Atincreased synthesis of nitric oxide (NO) and metabolism of L-arginine
to asymmetrical dimethylarginine (ADMA) and monomethyl-L-argi- pH 7.1, after only 31–55 h with 3.4 mM Leu, PD decreased (7.01 6
0.15 3 1023 log10 % of initial cellular 14C/h v 7.71 6 0.08 in controlsnine (L-NMMA). Release of cytokines during dialysis and heart failure
may down-regulate expression of eNOS and induce iNOS in vascular (P , 0.05)). After 72 h, 1.4 mM Leu increased total cell protein at pH
7.1 to 138.4 6 2.7 mg/22mm well v 131.8 6 2.8 in controls (P , 0.02).cells in chronic renal and heart failure. Moreover, pro-inflammatory
cytokines induce a parallel increase in the expression of the L-arginine In the same experiments there was no corresponding effect at pH 7.5
(161.0 6 2.4 v 160.4 6 2.6 in controls). In contrast the non-essentialtransports CAT-2 and CAT2A and iNOS in cardiac myocytes. In the
present study, we have examined L-arginine transport in red blood amino acid alanine (1 mM) had no effect on protein content at pH 7.1
(132.9 6 4.5 v 135.2 6 2.6 in controls), nor was significant improvementcells from chronic renal and heart failure patients. Transport of
L-arginine via system y1 from chronic renal and heart failure patients. observed with other metabolic fuels: glucose (20 mM), pyruvate (1
mM) or octanoate (1 mM). It is suggested that Leu selectively reducesTransport of L-arginine via system y1 (CAT-1) was increased in eryth-
rocytes from uraemic (700 6 92 mmoles. 121. h21., n 5 11) and heart acid-induced protein wasting by a mechanism involving regulatory
effects on protein turnover, rather than through acting as a metabolicfailure patients (490 6 60 mmoles. 121. h21., n 5 15) compared to
control (292 6 19 mmoles. 121. h21., n 5 10). L-arginine transport fuel to increase ATP supply. This is consistent with BCAA depletion
having a role in acid-induced PD, a depletion which may be accessiblevia system y1 was also dramatically increased in peripheral blood
mononuclear cells from chronic renal failure patients pre- (10.6 6 2.2 to nutritional therapy.
pmoles/l/106 cells/min, n 5 10, mean 6 S.E.M.) and post-dialysis (6.2 6
0.9 pmoles/1/106 cells/min, n 5 10) compared to control cells (2.3 6
0.5 pmoles/1/106 cells/min, n 5 10) (6). Plasma L-arginine levels were Ramipril reverses basal arterial constriction and attenuates myogenic
tone in the femoral artery in mild experimental uraemia. T. Savage,decreased in heart failure (59 6 3.7 mM) and renal failure (74 6 5.7
mM) compared to controls (125 6 mM), whilst the plasma concentration A.C. McMahon, A.M. Mullen,1 R. Tribe and M. Yaqoob, Anthony
Raine Research Laboratories, St. Bartholomew’s Hospital, 1Departmentof L-NMMA was elevated in these pathologies (uraemia: 8.8 6 1.8
mM and heart failure 3 6 1.3 mM and not detectable in control plasma). Fetal Health Research, St. Thomas’ Hospital, London. We have demon-
strated that vascular reactivity is altered in mild experimental uraemiaAll significance levels were p , 0.05. Our findings of decreased plasma
L-arginine levels and elevated plasma concentrations of L-NMMA as shown by increased myogenic tone and a reduced lumen diameter
in the femoral artery (RA 1997). We aimed to reverse this trend bytogether with increased rates of L-arginine transport may partially
explain the paradox that increased NO production serves as a failure intervention with the ACE-inhibitor Ramipril. 21 male wistar rats were
rendered uraemic (U) by 5/6th nephrectomy and 21 control (C) ratscounter-regulatory mechanism in chronic renal and heart failure pa-
tients. Supported by British Heart Foundation (PG/95102) were concurrently sham operated. After 4 weeks, half of each group
was given daily injections of 3 mg Ramipril for 4 weeks. A tail-cuff
systolic blood pressure (BP) (C 129 6 2 mmHg vs U 129 6 4 mmHg
p 5 ns) was then recorded and the rat sacrificed. Isolated femoralCalcitriol modulates IL6 gene transcription in osteoblast-like cells by
stabilisation of mRNA. N.J. Schroeder, C.W. McIntyre, J.M. Burrin1 arteries were mounted on a pressure myograph and pressurised at 40
mmHg for baseline measurements of the lumen internal diameter (i.d.).and J. Cunningham, Departments of Nephrology and Clinical Biochem-
istry1, St. Bartholomew’s and the Royal London School of Medicine and Myogenic tone was then assessed over a range of intravascular pressures
from 40–160 mmHg. The results were as follows (mean 1 SEM):Dentistry, London E1 2AD U.K. Both the release of IL6 (a potentially
important cytokine in the pathogenesis of osteodystrophy) and IL6
mRNA content of osteoblast-like cells is increased by calcitriol, al-
though it is not clear whether this reflects increased synthesis or stabili- C on U on
sation of IL6 mRNA. We have therefore performed experiments de- C Ramipril U Ramipril
signed to determine which of these processes mediates the effect of Variable (n 5 11) (n 5 9) (n 5 11) (n 5 10)
calcitriol on IL6 mRNA. Human osteoblast-like cells, MG63, were
Serum creatinine lmol /L 7065 72611 131613* 147617aincubated with calcitriol at 1027M (which we previously found to in-
Serum urea mmol /L 760.2 660.6 2266 2363aacrease IL6 secretion), 10211M (which did not) or IL1 (positive control)
Baseline i.d. lm 604633 721634 471630* 756622aafor 24hr and then continued with these treatments for a further 24hr
Myogenic tone % 2.360.4 3.461 7.362* 4.761in the presence of actinomycin D. Messenger RNA was extracted from
cells at 0, 1, 3, 6, 11 and 24 hr after addition of actinomycin D and *p , 0.01 controls vs. uraemics; ap , 0.01; aap , 0.0001 untreated versus treated
IL6 was measured semi-quantitatively by RT-PCR. The t1/2 of IL6
mRNA was determined by measuring the amount of product, relative
to GAPDH, for each time point, using scanning densitometry to give We conclude that the basal arterial constriction observed in mild exper-
the area ratio. The ratios were compared with the values at 0hr to imental uraemia is totally reversed by treatment with low dose Ramipril
generate a regression line. Initial results from duplicate samples showed and that myogenic tone is attenuated but not reduced to control levels.
the t1/2 of IL6 mRNA to be 11hrs in untreated cells. In the presence The results suggest that the mechanisms involved might be mediated
of calcitriol at 10211M the t1/2 was also 11hr but at 1027M the t1/2 was by renin or bradykinin or are consequent to longer term effects induced
increased to 27 hr. IL1, which greatly increased IL6 secretion and by direct action of Ramipril on vascular smooth muscle. Further studies
similarly up-regulated IL6 mRNA concentrations, increased t1/2 to 18 are needed to elucidate the mechanisms for these results.
hr. These results suggest that our previous observed increases in IL6
mRNA following exposure to calcitriol (1027M) or IL1 may be due
in part to effects on mRNA stabilisation. The N-terminal region may contribute to caesium sensitivity in ROMK
potassium channels. S. Bhandari and M. Hunter, Department of Renal
Physiology, University of Leeds, Leeds, UK. ROMK1 and ROMK2,
low-conductance inwardly rectifying K1 channels cloned from the ratLeucine reduces acid-induced protein wasting in L6 skeletal muscle
cells. A. Bevington, J. Brown and J. Walls, Dept. of Nephrology, Leices- kidney, regulate recycling and secretion of K1 ions across the apical
membrane of the thick ascending limb of the loop of Henle and distalter General Hospital, Leicester, UK. Skeletal muscle wasting during
uraemic metabolic acidosis arises largely from increased protein degra- nephron. Previously we have demonstrated differences in selectively
to thallium in ROMK1 and ROMK2. In the present study the interac-dation (PD) and is accompanied by increased catabolism of branched
chain amino acids (BCAA) which depletes intramuscular BCAA pools tion of caesium, a known potassium channel blocker, was examined.
50 nl of ROMK1 and ROMK2 cRNA were injected into collagenase (1(Bergstro¨m et al Kidney Int. 38 (1990),108). As certain amino acids
(including the BCAA leucine (Leu)) can inhibit PD, BCAA depletion mg/ml) treated Xenopus oocytes. Investigation using the two-electrode
voltage clamp amplifier confirmed expression of barium-sensitive K1could stimulate PD. L6 skeletal muscle cells were cultured for up to
72 h in MEM 1 2% serum at acidic pH (7.1) or control pH (7.5) to currents after 48 hours of incubation at 198C in modified Barth’s me-
dium. Bath solution contained in mM: 100 KCl, 1 MgCl2, 1 CaCl2, 10determine whether Leu supplements (1.4 or 3.4 mM) could reverse
Abstracts2554
HEPES, titrated to pH 7.4. Caesium in a concentration range of 1–100 cognising the CAMPATH-1H variable or constant region. The anti-
idiotypic YID13.9 monoclonal antibody was shown to bind with a KassmM was added to the bath solution for blocking studies. Results are
given as mean 6 SEM. Caesium produced concentration- and voltage- of 63 nM and 59 nM for two separate experiments. Next a series of
antibodies sharing only either their constant or variable region withdependent block of inward currents in both ROMK1 and ROMK2.
The Hill coefficients ranged from 1.2 6 0.2 at 2120 mV to 1.12 6 0.1 CAMPATH-1H were used to characterise anti-globulin responses of
patients. Ninety six control sera were screened for binding to immobi-at 260 mV for ROMK1 and 0.84 6 0.03 to 0.77 6 0.03 for ROMK2
respectively. These values for each channel were not significantly differ- lised CAMPATH-1H allowing criteria for positive binding to be estab-
lished. Sera from patients who had received multiple doses of CAM-ent from each other (p 5 0.7 and 0.1 respectively). The Kd (concentra-
tion of half-maximal block) decreased with hyperpolarisation in an PATH-1H were then studied. The binding of these sera to CAMPATH-
1H, CAMPATH-1G (shared idiotype with CAMPATH-1H), humani-exponential fashion. Dose response curves, fitted using the Hill equa-
tion, gave mean Kd values at 0 mV of 100.6 6 16.6 mmol/l (n 5 4) and sed anti-CD4 antibody (shared constant regions with CAMPATH-1H)
and soluble TNF receptor (shared heavy chain with CAMPATH-1H)40.6 6 9.4 mmol/l (n 5 6) for ROMK1 and ROMK2 respectively (p
, 0.05) and electric distances (d) of 0.94 6 0.06 and 1.27 6 0.05 was characterised. The antiglobulin response made by patients receiv-
ing multiple doses of CAMPATH-1H was shown to be polyclonal andrespectively. From the Woodhull equation for voltage-dependent block
the values of d ranged from 0.87 to 0.94 and 0.67 to 0.98 for ROMK1 high affinity but to remain restricted to the variable regions of the
therapeutic antibody.and ROMK2 respectively for the concentration range 5 to 50 mmol/
l. ROMK2 is significantly more sensitive (lower Kd) to caesium than
ROMK1. Structural differences between ROMK1 and ROMK2 lie in
the N-terminus, with ROMK1 containing an additional 19 amino acids. Investigation of the immunomodulatory function of pooled intravenous
immunoglobulin preparations. E.P. Pain, K.M. Gillespie, P.W. Mathie-This suggests that the N-terminal region may interact with the pore
of the channel to affect caesium blockage or this region contributes son and R.M. Smith, Academic Renal Unit, Southmead Hospital, Bristol.
Pooled intravenous immunoglobulin preparations (IVIg) are of provento the caesium-binding site directly. Dr. Sunil Bhandari is in receipt
of a National Kidney Research Training Fellowship and Kaberry Re- efficacy in treatment of autoimmune diseases (eg Kawasaki syndrome,
idiopathic thrombocytopenic purpura). Although some mechanisms ofsearch Grant.
action of IVIg have been characterised, the full spectrum of effects
on immune responses remains unclear. We have previously shown that
one such preparation (alphaglobin) has complex effects on expressionLow dose mercuric chloride (HgCl2) induces resistance in Brown-
Norway (BN) rats to full dose HgCl2 by up-regulation of interferon- of peripheral blood T cell activation markers suggesting a direct effect
on T cells. We now report the effects of IVIg on cytokine productiongamma (IFN-g). C.C. Szeto, K.M. Gillespie and P.W. Mathieson, Aca-
demic Renal Unit, Southmead Hospital, University of Bristol, Bristol, in human peripheral blood lymphocyte (PBL) proliferation assays.
Human PBLs were purified by density gradient centrifugation andBS10 5NB. Mercuric chloride (HgCl2) induces a Th2 type autoimmune
response in Brown-Norway (BN) rats. Pre-treatment with one-tenth stimulated with Pokeweed mitogen (PWM) in vitro for 24 h, 48 h or
72 h. Proliferation was assessed by tritiated thymidine incorporation.of the dose of HgCl2 does not itself induce autoimmunity, but leads
to resistance to subsequent full dose HgCl2. We have studied the mecha- Total RNA was prepared from parallel cultures at each time point and
reverse transcribed using AMVRT. Cytokine mRNA was quantifiednism of this resistance. Twenty BN rats were given low dose HgCl2
(0.1 mg/kg subcutaneously alternate day for 5 doses) and then rechal- by PCR amplification using primers designed to bridge intron exon
boundaries. Total cDNA was equalised for each reaction usinglenged with standard dose of HgCl2 (1 mg/kg subcutaneously alternate
day for 5 doses). Another 10 BN rats were only given standard dose GAPDH PCR. Alphaglobin inhibited lymphocyte proliferation at all
time points studied, this effect titrating from 10 mg/ml to 2 mg/ml.HgCl2. Cytokine profile was examined by semi-quantitative RT-PCR
of splenic RNA. Serum IgE and interferon gamma (IFN-g) were as- PWM stimulation increased IFN-g, IL-10 and IL-13 mRNA in all
experiments. Alphaglobin inhibited this increase in IFN-g and IL-10sayed by ELISA. We found modest increase in serum IgE level (1.93 6
1.20 to 22.34 6 4.16 mg/l) when rats were given low dose HgCl2 (cf. mRNA at all time points, but no effect was seen on the level of IL-
13 mRNA. The effect on IFN-g and IL-10 mRNA was seen with bothstandard dose HgCl2: 3.88 6 1.08 to 22754 6 983 mg.l), and no up-
regulation of IL-4 mRNA expression. There was up-regulation of 10 mg/ml and 2 mg/ml of Alphaglobin but was again more marked at
the higher dose. The use of GAPDH PCR to equalise total cDNA forIFN-g mRNA expression at day 10 of low dose HgCl2, while serum
IFN-g level rose on day 30, from 364.3 6 14.1 to 488.7 6 84.7 pg/ml. each reaction and the selective effects on IFN-g and IL-10 mRNA
but not IL13 mRNA exclude these effects being secondary to theThere was simultaneous up-regulation of IL-12 receptor b2-chain (IL-
12Rb2) expression with that of IFN-g. IL-10 and TGF-b expression antiproliferative effect of IVIg. This selective modulation of cytokine
profiles may be important in the ability of IVIg to inhibit autoimmuneremained static, while IL-12 and IL-18 showed transient down-regula-
tion. Animals were resistant to subsequent full-dose HgCl2. Our obser- disease processes. The specific pattern seen would suggest particular
efficacy in inhibiting Th1 dependent immune responses.vations suggest that low dose HgCl2 confers resistance to full-dose
mercury by up-regulating IFN-g, which causes preservation of IL-
12Rb2 expression.
Early vasculitis in the mercuric chloride induced Brown Norway rat
model is neutrophil independent. F.E. Harris, D.R. Turner and D.B.G.
Oliveira, Division of Renal Medicine, St. George’s Hospital MedicalCharacterisation of antiglobulin responses to a humanised therapeutic
monoclonal antibody using the resonant mirror biosensor. R.M. Smith1, School, London. In the Brown Norway (BN) rat, mercuric chloride
(HgCl2) induces an autoimmune syndrome characterized by necrotizingM. Wing2 and M.R. Clarke3, Academic Renal Unit, Southmead Hospital,
Bristol1, Department of Neurology, Addenbrookes Hospital, Cam- leucocytoclastic vasculitis, predominantly in the caecum, and a poly-
clonal B-cell response. Vasculitis is found within 24 hours of HgCl2bridge2 & Department of Pathology, Cambridge University3. The inher-
ent specificity of antibodies makes them attractive as immunosuppres- injection, although both tissue injury and antibody response are maxi-
mal at two weeks. Peak disease has been shown to be T-cell dependent,sive agents. However antibody molecules are themselves proteins
capable of eliciting immune responses which may neutralise the thera- but early vasculitis is ab T-cell independent. Neutrophil depletion at
peak disease using a monoclonal antibody (RP3) ameliorates tissuepeutic action of the antibody or result in anaphylaxis. In order to
prevent such antiglobulin responses a number of therapeutic antibodies injury. We aimed to examine the role of the neutrophil in early vasculitis
using both RP3 and cyclophosphamide-induced neutropaenia. In 4have been humanised. However, the variable region of the antibody
(idiotype) inevitably remains “foreign” and may leave a residual target experiments, 56 rats received either intraperitoneal cyclophosphamide
or vehicle, RP3 or a control antibody, in varying doses, 1 to 4 daysfor immune recognition. We have used resonant mirror biosensor
(IAsys) technology to detect and characterise antiglobulin responses prior to HgCl2. HgCl2, 0.1 mg/kg, was injected subcutaneously on day
0, and in 2 of the 4 experiments, on day 2. Serial measurements ofto the humanised CAMPATH-1H antibody. The IAsys Auto1bio-
sensor has been used for this work. This technique was first validated peripheral blood leukocyte count were made. Rats were killed on day
1 or 3. The macroscopic appearance of the caecum was scored by anby coupling CAMPATH-1H to a carboxymethyl dextran sensing sur-
face and characterising binding of purified monoclonal antibodies re- experienced observer, and samples taken for histological examination.
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Caecums were excised, myeloperoxidase (MPO), a marker enzyme for myofibroblasts in addition to anti-fibrotic effects generally. We have
examined the effects of IFN-g on the progression of renal fibrosismeasuring neutrophil infiltration, extracted and it’s activity measured.
Cyclophosphamide induced neutropaenia within 48 hours of injection, following subtotal nephrectomy (SNx) in the rat. Animals were divided
into 3 groups; Group 1 – Sham, Group 2 – SNx plus vehicle andwith the nadir (0.07 3 106/ml) after 4 days. RP3 reduced the neutro-
philia observed after HgCl2 injection. Macroscopic evidence of vasculi- Group – B SNx plus IFN-g. IFN-g was delivered directly into the renal
parenchyma at a dose of 400 units/day for 1 month following surgerytis was observed in 18/20 animals killed at day 1 and in 36/36 animals
killed at day 3. Histological evidence of vasculitis was present in both by means of a fenestrated cannula connected to a subcutaneous osmotic
minipump. Rats were sacrificed on days 15, 30, 45, and 90 after SNx.treated and control animals, with no significant differences in macro-
scopic or microscopic scores between the groups. Tissue myeloperoxi- Clinical data showed a marked reduction in proteinuria in Group 3
when compared to Group 2 at day 90 (240 6 44 vs. 465 6 53 mg/day,dase activity was low in all animals and did not differ significantly
between the groups. The data support the hypothesis that neutrophils p , 0.01) accompanied by a significant preservation of CrCl up to day
45 (1.18 6 0.08 vs. 0.90 6 0.06 ml/min, p , 0.05). Immunohistochemicalare not necessary in the initial pathogenesis of vasculitis in the HgCl2
treated BN rat model. staining for a-smooth muscle actin (a-SMA), a phenotypic marker of
myofibroblast activation, was significantly increased in both glomeruli
and interstitium in Groups 1 and 2 form day 30 onwards; Group 3 had
significantly lower scores for a-SMA staining in glomeruli at all timeTherapeutic effect of osteogenic protein-1 in experimental crescentic
nephritis. A.M. Karkar, A. Allen, T. Cook, J. Smith, S. Fawell1, K. points (p , 0.05) and tubulointerstitium up to day 45 (3.0 6 1.0 vs.
7.91 6 1.2%, p , 0.05). Fibrosis scoring revealed a reduction in bothLoveday2 and C.D. Pusey, Renal Section, Division of Medicine, Imperial
College School of Medicine, Hammersmith Hospital London, UK, Bio- glomerulosclerosis up to day 30 (0.11 6 0.05 vs. 0.27 6 0.05, p , 0.05)
and tubulointerstitial fibrosis up to day 45 (1.0 6 0.03 vs. 1.65 6 0.07,gen1, Cambridge, MA, and Creative Biomolecules2, Hopkinton, MA,
USA. Osteogenic protein-1 (OP-1) or bone morphogenetic protein-7 p , 0.05) in Group 3 when compared to groups 1 and 2. These data
support other recent findings of a renoprotective effect of IFN-g (JASN(BMP-7) is a member of the TGF-b superfamily. OP-1 is a potent
bone morphogen and the adult kidney is its major site of production. 8: 465A, 1997), particularly regarding proteinuria. They also suggest
that the anti-fibrotic properties of IFN-g may be mediated, at least inMice lacking OP-1 display defects in kidney development, and in vitro
studies showed that OP-1 can induce formation of renal tubules from part, through its inhibitory effects on the activation of myofibroblasts
during the early stages of fibrosis.mesenchymal cells. Furthermore, levels of OP-1 mRNA decrease sig-
nificantly after injury to the kidney, and exogenous OP-1 has recently
been reported to protect against renal injury following ischemia in
rats. In the present study, we have investigated the role of soluble Human mesangial cells express inducible macrophage scavenger recep-
tor. Xiong Z. Ruan, Zac Varghese, Rehan L. Fernando, Stephen H.OP-1 as treatment for nephrotoxic nephritis (NTN) in Wistar-Kyoto
(WKY) rats. This is a model of crescentic nephritis in which glomerular Powis and John F. Moorhead, Centre for Nephrology, Royal Free
Hospital School of Medicine, London, UK. Scavenger receptors (Scr)injury is dependent on CD81 cells and monocytes/macrophages. Our
aim was to study whether continuous administration of soluble OP-1, mediate the uptake of modified low density lipoproteins by macro-
phages. The accumulation of lipid through this process is thought toin different doses, following the establishment of crescentic nephritis,
would inhibit the development of renal failure. Nephritis was induced lead to foam cell formation in developing atherosclerotic plaques.
Human mesangial cells (HMCs), which can also be converted to foamby a single intravenous injection of 0.1 ml of nephrotoxic serum in 24
WKY rats. At day 7, when glomerular crescents are known to have cells in vivo, have not previously been shown to express scavenger
receptor (Scr) in normal HMCs in culture. This study investigatedformed, rats were divided into four groups (n 5 6). Recombinant
human (rh) soluble OP-1 was administered intraperitoneally every whether a human mesangial cell line (HMCL) expressed an inducible
form of Scr and, if so, how its transcription was regulated. Scr activityother day at 30, 100 or 300 lg/kg doses. The control group received
rhOP-1 buffer alone. All rats were killed at day 25 after induction of was analysed by cellular uptake of fluorescently labelled acetylated
nephritis. Results (mean 6 SEM) are shown below (ap 5 0.026, bp 5 low-density lipoprotein using a flow cytometer. Scr mRNA expression
0.041 by Mann-Whitney U test): was examined using RT-PCR followed by Southern blotting. To investi-
gate the mechanism of Scr transcription, several reporter gene con-
structs were designed and transfected into HMCL. The first reporter
(A) contained the full Scr promoter; the second (B) contained onlyCreatinine
that part of the Scr promoter region containing AP-1/ets transcriptionalOP-1 dose Albuminuria S. creatinine clearance
factor binding sites, and others were identical to (B) except they con-lg/kg mg/day lmol /l ml /min
tained mutations within either AP-1 or ets. Results showed that HMCL
30 292626a 95610b 0.7360.09b expressed inducible Scr mRNA and its protein in a dose and time
100 312632 94 68a 0.7760.10b dependent manner when stimulated by phorbol 12-myristate 13-acetate
300 394634 119 67 0.5760.02 ( PMA). PMA also significantly increased Scr promoter activity in a
Vehicle 400631 142 620 0.4860.06 dose and time dependent manner. Promoter mutation analysis demon-
strated that either AP-1 or ets mutation significantly decreased PMA
induced Scr expression. In conclusion, this study suggests that HMCL
expresses inducible Scr and that both AP-1 and ets transcriptionalBy histological analysis, OP-1 treatment reduced tubulointerstitial
factors are necessary for induction of expression.damage, but there was no difference in the prevalence of fibrin deposi-
tion or crescent formation when compared with the control group.
However, treatment with OP-1 caused a substantial reduction in glo-
A local confidential inquiry into management of hypertension in pa-merular expression of adhesion molecules ICAM-1 and VCAM-1, and
tients developing end-stage renal failure. I. Dasgupta, J. Savill, M.marked reduction in tubular expression of ICAM-1. In conclusion,
Pringle, R. Madeley and R.P. Burden, Renal Unit, Nottingham CityOP-1 exerts anti-inflammatory effects in glomerulonephritis and may
Hospital, Nottingham, U.K. A large part of nephrological practice isplay an important role in the protection of renal tubules against immune
aimed at the identifying factors which—if untreated—may cause ormediated injury.
aggravate chronic renal failure. This study was designed to determine
how well this is achieved, with particular attention to management of
hypertension. During the past three years, 145 adults from a singleIntra-renal administration of interferon-g (IFN-g) inhibits myofi-
broblasts and reduces experimental renal scarring. S.D. Oldroyd, G.L. health district started dialysis (yearly acceptance approximately 75
pmp). General Practice and hospital records were examined and allThomas, G. Gabbiani1 and A.M. El Nahas, Sheffield Kidney Institute,
Northern General Hospital, Sheffield UK and Dept. of Pathology1, Uni- entries relating to renal disorders and hypertension were compared
with generally accepted protocols for investigation and treatment basedversity of Geneva, Switzerland. Clinical and experimental evidence
indicates that myofibroblasts play a key role in renal fibrosis. Recent on British Hypertension Society and Renal Association standards. In
addition to direct comparison with standards the data was revieweddata have ascribed to the cytokine interferon-g an inhibitory effect on
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by two independant assessors, one a GP and the other a consultant of the relative importance of tubular secretion of creatinine. In patients
on CAPD, the amount of tubular secretion of creatinine falls as residualrenal physician.
145 patients: records complete in 142 renal function falls. Therefore, the calculated creatinine clearance may
be reasonably accurate in patients on CAPD. We have used the creati-Median age 60 years (range 20 to 82); 95 M, 47 F; mean period of
observation: 18.4 years 6 0.9 (SE) nine clearance calculated by the method of Cockcroft and Gault (ad-
justed to litres/week) and compared it with the measured creatinineMedian no. of BP readings 53 (range 11 to 201).
107/142 patients (76%) diagnosed hypertensive before ESRF of whom: clearance using a standard technique in 35 patients on CAPD. The
Pearsons correlation coefficient between the measured and calculated• No creatinine measured within 12 months of diagnosis 25%
creatinine clearance in 35 patients on CAPD was 0.82 (p 5 0.000).• No urinalysis done within 12 months of diagnosis 30%
There was no correlation with Kt/V for the same patients.• Antihypertensive treatment delayed by .6 months 13%
• Mean BP at the start of treatment (mmHg) 182.8/109.4 6 2.5/1.5
(SE)
• Mean BP throughout time of observation (mmHg) 159/91 6 1.3/0.7
(SE)
• Mean diastolic BP #90 mmHg (BHS standard) achieved in 45%
• Mean BP #140/90 (RA standard) achieved in 20%
• Creatinine #350 (mmol/l) at referral to renal unit achieved in 50%
• Significant delay in referral to the renal unit 22%
• Poor BP control contributed to progression 32%
In conclusion, there were shortcomings in all aspects of the manage-
ment of hypertension in patients developing ESRF, the most important
of which was control of BP. In 32% cases this was thought to have
contributed to the progression of renal failure.
A study of HIV-positive patients receiving dialysis for ESRF in the
UK in 1996. A.G. Stein, C.P. Breen and B.M. Hendry, Renal Medicine,
King’s College Hospital, King’s College School of Medicine and Den-
tistry, London, UK. 29 HIV-positive patients who received dialysis for
The calculated creatinine clearance, therefore, offers a reasonable ap-endstage renal failure (ESRF) in the UK at any time in 1996 were
proximation to the measured clearance which is itself prone to erroridentified by communication with all UK renal units. 24 of these were in
because of the complex collection procedures. Its use would reduceLondon units and 69% were male. 17 were West African, 7 Caucasian, 4
the trouble to patients, nurses and biochemists and provide cliniciansAfro-Caribbean and 1 Asian. Identified risk factors for HIV were
with a more accessible guide to therapy.sexual orientation in 9, haemophilia in 2 and i.v. drug use in 2, all the
17 West Africans were heterosexual. Hepatitis B serology was positive
in 8, and hepatitis C in 4. The renal diagnosis was HIV-associated
Analysis of increasing delivered dialysis dose in malnourished perito-nephropathy (HIVAN) in 15 cases, haemolytic uraemic syndrome in
neal dialysis patients. S.J. Davies, L. Philips, A. Griffiths, P.F. Naish3 and another glomerulonephritis in 5. The diagnosis of HIV was
and G.I. Russell, Renal Unit, North Staffordshire Hospital Trust, Stoke-known before presentation with ESRF in 10 cases; in these patients
on-Trent, UK. As residual renal function (RRF) is lost in peritonealthe median time between HIV diagnosis and ESRF was 30 months
dialysis (PD) patients, malnutrition worsens and is associated with an(range 1–176). 17 cases presented acutely with the need for immediate
increased risk of death. The influence of increasing peritoneal clear-dialysis. The initial outpatient dialysis modality was CAPD in 19 and
ances of small solutes (KT/V) remains unclear. We have performed anhaemodialysis in 10. 1 year survival with ESRF was 81% (21/26) and
open, non-randomised, prospective, ”intention to treat”, longitudinal2 year survival was 42% (8/19). The mortality for patients with HIVAN
intervention study in malnourished PD patients. During the enrolmentwas 60% (9/15), compared to 21% (3/14) for patients with another
period (1995–6), 46 of 151 patients on PD for at least 6 months wererenal diagnosis (p , 0.05, chi squared). Of the 19 who started on
defined as malnourished by a subjective global assessment score (SGA)CAPD, 7 have died and 6 are alive on HD, 5 remaining on CAPD at
of B or worse and/or being 5% below desirable body weight, despitelatest follow-up (1 recovered renal function). In 8 cases started on
receiving dietetic advice and nutritional supplements. Compared toCAPD severe peritonitis occurred (including 5 due to pseudomonas) their well nourished contemporaries they had been on dialysis longerleading to 4 deaths and 4 technique failures. In conclusion, HIV- (36 v. 20 months) had much less RRF (weekly KT/V: 0.15 v. 0.65),positive patients who start dialysis for ESRF in the UK have a median higher peritoneal solute transport (D/Pcreat 0.71 v. 0.66), lower mid-survival of just under 2 years. In 66% of patients the initial choice of arm circumference (MAC 26.5 v. 29.3 cm), lower protein catabolicESRF treatment modality is CAPD but this is associated with a high rate (PCR 62.1 v. 76.7 g/day) and plasma albumin (31.8 v. 36.4 g/l),
rate of technique failure and only 29% of patients alive at latest follow- all P , 0.05. The longitudinal evolution of these parameters beforeup were on CAPD. The number of HIV-positive ESRF patients identi- and after the intervention, which was a 25% increase in delivered KT/fied represents a prevalence of 0.1–0.15% of patients with ESRF in V, are shown in the table:the UK.
Assessment of adequacy of CAPD. C.M. Stirling and J.M. Boulton-
Jones, Renal Unit, Royal Infirmary, Glasgow. The assessment of the
Months before and after interventionefficacy of CAPD is a formidable logistic operation requiring simulta-
neous collections of all effluent peritoneal fluid and urine over a mini- 212 26 22 0 2 4 6
mum period of 24 hours. The Renal Association has set a weekly
Weight Kg 67.8 67.6 67.6 66.3* 66.4 65.8 66.3creatinine clearance greater than 50 L/week as a minimum standard
MAC cm 27.8 26.7 27.1* 27.4 27.5§and required that the measurement be repeated at least annually.
KT/VTOTAL 1.83 1.65 1.56* 1.79§One of the advantageous of CAPD over haemodialysis is that it is a
PCR g/day 72.4 65.1 62* 65.4§continuous process which results in a steady state. It may, therefore, be
Albumin g/l 35.3 34 32.3 31.7* 30.8 32.2 33.4§possible to calculate the creatinine clearance from the serum creatinine
SGA score 5.5 5.16 4* 4.5 5.1 5.2§using an established method such as that of Cockcroft and Gault which
uses age, sex and weight. This calculated creatinine clearance was *Significant decline prior to intervention, §significant improvement following
intervention, P , 0.05found to be least accurate in patients with low renal function because
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Five deaths occurred in the 6 month follow up period, but these were (NC, n 5 4) and cultured in colony assays containing various concentra-
tions of EPO and autologous serum (5% v/v). Additionally, bonenot responsible for the apparent improvement in nutritional state
achieved by increasing KT/V in the context of dietetic nutritional marrow from NC were cultured with 3U/ml EPO plus sera from either
NC (n 5 6), uraemic controls (UC, n 5 10) or UI (n 5 10) with orsupport.
without antibodies to TNFa or IFNg. CFU-E were counted on day
10 (mean 6 SD). Additionally, bone marrow from NC were incubated
for 24 hours with sera from either NC, UC or UI. Medium was collectedUltrastructural abnormalities of kidney and lung in a rat model of
Goodpasture’s disease. J. Reynolds, J. Moss1, J. Smith, A.M. Karkar, and cytokine concentrations measured. There was no difference be-
tween NC and UI bone marrow response to EPO, however, when UII. Shore1, D.J. Evans2, D.F. Woodrow1 and C.D. Pusey, Renal Section,
Division of Medicine, Hammersmith Hospital, and Departments of His- bone marrow was cultured with autologous serum the optimal response
to EPO was significantly inhibited. Optimal CFU-E formation wastopathology, 1Charing Cross Hospital and 2St. Mary’s Hospital, ICSM,
London. Experimental autoimmune glomerulonephritis (EAG) can inhibited by sera from UC and UI (UC 30 6 7**; UI 22 6 10** vs
NC 54 6 11, **P , 0.001). Anti-TNFa and anti-IFNg antibodiesbe induced in WKY rats by immunisation with collagenase-solubilised
rat GBM in FCA. In order to characterise ultrastructural changes partially reversed inhibition by UI and when combined completely
reversed inhibition by UC and UI (UC 1 Abs 57 6 7** vs UC 30 6associated with the development of crescentic nephritis and pulmonary
haemorrhage in this model of Goodpasture’s disease, groups of rats 7, UI 1 Abs 52 6 16** vs UI 22 6 10, **P , 0.001). Serum-stimulation
of cells from NC resulted in increased production of IL-1a and IFNg.were killed at weeks 1, 2, 3 and 4 after immunisation. Circulating anti-
GBM antibodies and albuminuria were detected by week 2, increased Cells stimulated with sera from UI showed the greatest increase in
the production of both cytokines (IL-1a 12.1 6 3.3* pg/ml, IFNg 89 6by week 3, and peaked at week 4. A decrease in creatinine clearance
was observed at weeks 3 and 4. Direct IF for IgG showed weak, 4.0** pg/ml compared with UC or NC, *P , 0.01, **P , 0.001). TNFa
was detected in the sera of UC and UI. We conclude that a serum-intermittent deposits on the GBM at week 2, and strong linear deposits
of IgG along the GBM, and to a lesser extent the TBM, at weeks 3 and soluble factor, not a bone marrow defect, is responsible for the resis-
tance to EPO in UC and UI, and that sera from these patients stimulates4. Large deposits of fibrin, mainly in Bowman’s space, were observed at
weeks 3 and 4. Immunohistological and single cell FACS analysis of inflammatory cytokine production from mononuclear cells in vitro
which in turn inhibit CFU-E formation.glomerular cells demonstrated that infiltration with T cells preceded
an influx of macrophages. Light microscopy showed slight glomerular
abnormalities by week 2, which increased by weeks 3 and 4, when
there was severe focal and segmental necrotizing glomerulonephritis, Blockade of very late antigen-4 reduces renal injury in a rat model of
nephrotoxic nephritis. A. Allen, J. Smith, T. Cook and C. Pusey, Renalwith numerous crescents. This was accompanied by interstitial damage
and tubular atrophy. An increase in T cells and macrophages was Section, Division of Medicine, Imperial College School of Medicine,
Hammersmith Hospital, London, UK. There is interest in the capacityobserved in the lung at weeks 3 and 4, together with large areas of
pulmonary haemorrhage. The Table shows mean results for groups of of therapies directed at cell adhesion molecules to reduce leukocyte
migration into the kidney during glomerulonephritis and to lessen renalrats (n 5 5) at different times after immunisation.
injury. Nephrotoxic nephritis (NTN) in the WKY rat is a model of
crescentic glomerulonephritis (CGN) characterised by the accumulation
of monocytes/macrophages and CD8 1ve cells in glomeruli and progres-Weeks 0 1 2 3 4
sive renal impairment. Treatment with monoclonal antibodies (mAbs) to
Anti-GBM ab % 20 25 60 82 94 the leukocyte integrin lymphocyte function associated antigen-1 (LFA-1)
Albuminuria mg/day 0 0 40 254 465 and/or intercellular adhesion molecule-1 (ICAM-1) has previously
T cells/macrophages per 50 glom 18/0 22/2 55/4 92/84 120/144 been shown to inhibit both leukocyte migration into the kidney and
Abnormal/crescentic glom % 0/0 0/0 21/0 85/45 100/60 development of CGN in this model. In this study, we examined the
expression of vascular cell adhesion molecule-1 (VCAM-1) and investi-
gated the effects of treatment with mAbs to VCAM-1 or its leukocyte
integrin ligand, very late antigen-4 (VLA-4). ImmunohistochemistryElectron microscopy showed moderate focal ultrastructural changes
demonstrated that VCAM-1 was upregulated at the protein level inwithin the glomeruli by week 2, which increased in severity by weeks
both glomeruli and interstitium after day 4 of NTN. Therapeutic studies3 and 4. In less severely affected segments there was endothelial cell
were performed with blocking mAbs to VCAM-1 (5F10, murine IgG2aswelling, and as the lesion progressed the mesangium became expanded
anti-rat VCAM-1, 5 mg/kg) and VLA-4 (TA-2, murine IgG1 anti-ratby numerous mononuclear cells. In some instances, there was detach-
a4 integrin, 2.5 mg/kg). Isotype matched murine mAbs were used asment of the endothelium from the GBM and accumulation of fibrin
controls at the same doses (P1.17 IgG2a, 1E6 IgG1). Nephrotoxicbeneath the disrupted endothelial cells and in the crescent. Occasional
serum was given on day 0 to induce disease and mAbs were given bybreaks were observed in the continuity of the basement membrane,
intraperitoneal injection on days 21, 1, 3 and 5. All rats were killedand cytoplasmic projections from infiltrating mononuclear cells could
on day 7 after a 24-hour urine collection. Renal histology was scored bybe seen crossing the capillary wall between the lumen and the crescent.
a blinded observer (TC) and intraglomerular monocytes/macrophagesUltrastructural analysis of lung tissue showed focal inflammatory cell
were counted using immunohistochemistry with mAb ED1. Resultsinfiltrates in capillaries and alveolar walls at weeks 3 and 4. Occasional
(mean 6 SEM) are shown below (ap , 0.05, bp , 0.01):breaks were observed in the capillary basement membrane and adja-
cent endothelium, together with focal regions of haemorrhage. This
study defines the relationship between immunological and pathological
events in EAG, and provides insight into the immunopathogenesis of Glomerular
Goodpasture’s disease. Glomeruli quadrants
Albuminuria with with ED1 positive
mAb No. in on day 6–7 crescents fibrinoid cells per
A serum soluble factor promotes cytokine-mediated bone marrow treatment group mg/day % necrosis glomerulus
suppression in uraemic patients with inflammatory disease. D.A. Allen1,
5F10 6 134 6 12 58 6 4a 1.4 6 0.1 30 6 3C. Breen2, I.C. Macdougall2 and M.M. Yaqoob1, 1Anthony Raine Re-
P1.17 5 158 6 16 74 6 5 1.6 6 0.2 32 6 4search Labs, St. Bartholomew’s and Royal London School of Medicine
TA-2 6 32 6 15b 32 6 3b 0.7 6 0.1b 28 6 3and Dentistry, and 2Renal Unit, King’s College Hospital, London. Resis-
1E6 5 182 6 17 74 6 4 1.6 6 0.1 30 6 3tance to erythropoietin (EPO) in uraemic patients with infection or
inflammatory disease is well documented but the mechanisms are un-
known. In the present study bone marrow cultures were used to assess
the relationship between cytokines and erythropoiesis in uraemia. The greater therapeutic efficacy of anti-VLA-4 antibody than anti-
VCAM-1 antibody has been observed in other organ systems, andBone marrow was obtained from uraemic patients with resistance to
EPO due to inflammatory disease (UI, n 5 7) and from healthy controls this study confirms such an effect in glomerular inflammation. The
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significant inhibition of renal injury by TA-2, without reduction in alter total cellular Ras protein or the above ratio. The pulse-chase
results demonstrated that 400 nM Ki-ras oligo reduced Ras synthesisglomerular leukocyte numbers was an unexpected finding, and suggests
that monocyte VLA-4 may have a greater role in activation than in and increased the fractional farnesylation of newly-synthesised Ras.
These results suggest that the stimulation of vero 19 proliferation bymigration into the kidney.
EGF and FGF is at least partially dependent upon Ki-Ras. The activa-
tion of Ras by farnesylation appears to be upregulated when Ki-Ras
synthesis is impaired. Ki-Ras may therefore be a target for therapySystemic antibody response to Helicobacter pylori infection in IgA
nephropathy. A.C. Allen, J. Barratt, E.M. Bailey, J.C. Mailley, J.E. designed to inhibit renal fibroblast proliferation in the context of pro-
gressive renal disease.Crabtree1, P.A. Johnston2, A.M. Brownjohn2, J. Feehally and J.H. Tur-
ney2, Dept of Nephrology, Leicester General Hospital, Leicester, UK,
1St. James’ University Hospital, Leeds, UK, and 2The General Infirmary
at Leeds, Leeds, UK. Helicobacter pylori (Hpy) is a mucosal pathogen Vascular permeability factor mRNA isoform and receptor expression
in isolated single human glomeruli from normal subjects. C. Whittle,which elicits both mucosal and serum antibody responses in infected
individuals. In IgA nephropathy (IgAN), mucosal polymeric IgA P.W. Mathieson and S.J. Harper, Richard Bright Renal Unit, Southmead
Hospital, Bristol. Vascular permeability factor (VPF) mediates in-(pIgA) production is deficient, while systemic pIgA production is in-
creased. To further investigate this imbalanced IgA production, we creased vascular permeability and has been implicated in normal glo-
merular permselectivity and in proteinuric states. Differential splicingstudied serum anti-Hpy responses in Hpy breath test positive subjects:
23 patients with IgAN and 9 controls. Serum anti-Hpy antibody levels of the VPF gene produces four functionally distinct isoforms: -VPF206;
VPF189; VPF165; & VPF121. VPF receptors may be stimulatory, KDRwere measured in Hpy antigen-specific ELISAs, detecting bound anti-
body with peroxidase-conjugated anti-IgA, -IgG or -IgG subclasses and membrane bound FLT (mFLT) or inhibitrary—soluble FLT
(sFLT). We have studied the patterns of expression of VPF isoforms1-4. The number of IgAN and control subjects producing each species
of anti-Hpy were compared by x2 test with Yates’ correction. 17/23 and VPF receptors in normal glomeruli. 91 glomeruli from 11 nephrec-
tomy specimens were studied. Single glomeruli were immersed in DY-IgAN subjects produced IgA anti-Hpy, but none of the control subjects
did so (p , 0.001). Serum IgG anti-Hpy was detected in both groups NAL lysis buffer, mRNA harvested onto magnetic beads and nested
RT-PCR performed using primers for the VPF isoforms and VPF-(21/23 IgAN patients and 8/9 controls; p 5 NS), but the pattern of
IgG subclasses was strikingly different. In the controls, IgG3 anti- receptors. Simultaneous nested PCR for CD45 was conducted to ex-
clude leucocyte contamination. 7 patterns of glomerular VPF mRNAHpy predominated (5/9 subjects), with IgG4 (3/9) and IgG1 (2/9) also
represented, but no control produced IgG2 anti-Hpy. In marked con- isoform expression were identified:
trast, 21/23 IgAN patients produced IgG2 anti-Hpy (p , 0.001 vs
controls); production of the other IgG subclasses did not differ from
controls (IgG1 14/23, IgG3 16/23, IgG4 10/23). These data demonstrate VPF Isoform Profile % glomeruli
a striking difference in the serum antibody response to a mucosal profile composition n sampled
antigen in IgAN. Serum IgA and IgG2 antibodies to Hpy were found
1 121 8 8.6in IgAN but not in controls, providing further evidence for a shift of
2 121,165 22 24.2mucosal-type IgA production to a systemic location, and indicating
3 121,165,189 46 50.7that IgA and IgG2 are probably controlled by similar factors. The
4 121,189 3 3.3abnormal occurrence of both these antibody species in the serum of
5 165 5 5.5patients with IgAN suggests that in this disease, the underlying immune
6 165,189 4 4.4defect leading to raised systemic IgA originates at the controlling T
7 189 3 3.3cell or cytokine level.
Antisense oligonucleotides demonstrate a role for Ki-Ras in the stimu- No difference in the patterns of isoform expression was evident com-
lated proliferation of primate renal fibroblasts. C.C. Sharpe, M.E.C. paring surface cortical to juxta-medullary glomeruli. VPF-receptor RT-
Dockrell, M.I. Noor, A.F. James, B.P. Monia* and B.M. Hendry, Renal PCR showed that KDR is expressed by 58% of normal glomeruli,
Group, Department of Medicine, King’s College School of Medicine mFLT in 25% and sFLT by 70%. This is in line with in vitro results
and Dentistry, London, UK and *ISIS Pharmaceuticals, Carlsbad, Cali- from cultured podocytes in our laboratory. In conclusion the expression
fornia, USA. Multiple cytokines are implicated in the proliferation of of VPF within a population of normal glomeruli is complex and variable
interstitial fibroblasts which occurs in progressive renal fibrosis. The but the majority of glomeruli (83.5%) express one, two or all of the
p21-Ras family of GTPases function at a point of intracellular conver- three smaller forms. Furthermore sFLT appears to be the dominant
gence of many of these signals. This study investigates the role of form of VPF receptor expressed within glomeruli suggesting that in
specific Ras isoforms in the stimulated proliferation of renal fibroblasts. health VPF autoregulation is the norm.
Specific antisense phosphorothioate oligodeoxynucleotides (oligos)
targeted to the Ki, Ha and N isoforms of ras (ISIS 6957, 2503, and
14691) have been compared with a control oligo of equal size (ISIS A single amino acid change in the class II transactivator results in
13177). Cells of a primate renal fibroblast cell line (vero 19) were malfunction of this protein and complete absence of class II expression.
transfected with oligo (200–400 nM, 6–17 hours) using lipofectin. Sub- V. Quan, M. Towey, S. Sacks, P. Amlot1 and A. Kelly, Department of
sequent proliferation was assessed by cell number assay (MTS) in nephrology and transplantation, UMDS, Guy’s Hospital, London, UK
conditions of growth stimulation by serum, FGF or EGF. The total and Department of immunology1, Royal Free Hospital, London, UK.
cellular expression of Ras proteins was assessed by immunoprecipita- The class II transactivator (CIITA) is one of several trans-acting factors
tion (IP) and Western blotting using pan-Ras monoclonal antibodies. necessary for transcription of class II genes. Unlike the other factors
The synthesis of Ras in the 4 hour period after transfection was mea- which are ubiquitously expressed, CIITA expression is detected only
in cells expressing class II, is the mediator of IFN-y inducible class IIsured using a pulse-chase of [35S]-cys/met followed by IP with Y13-259
and autoradiography of p21-Ras after PAGE. Inactive non-farnesy- expression, and is necessary and sufficient to induce class II expression
in a range of normally negative cells. CIITA can therefore be seen aslated Ras and the active farnesylated form could be quantified as
discrete bands. Transfection with Ki-ras oligo (200 nM) decreased EGF a master switch for class II expression. Patients with the inherited
immunodeficiency disease Bare Lymphocte Syndrome (BLS) do notand FGF-stimulated cell proliferation over the following 48 hours by
20–35% compared to control oligo; 200nM Ha-ras and N-ras oligos express class II antigens. We have analysed an EBV transformed B
cell line (Fern) from a BLS patient and shown that lack of class IIwere inactive with respect to the control. Serum-stimulated growth
was also inhibited by the Ki-ras oligo but to a lesser extent. Total expression is due to defective CIITA, transfection with normal CIITA
cDNA restoring the full class II positive phenotype. Semi-quantitativecellular Ras protein 24 hours after transfection was reduced by 400
nM Ki-ras oligo which also reduced the ratio of non-farnesylated to pcr suggests Fern expresses CIITA message in amounts comparable
to class II positive cells. Sequencing of the Fern CIITA cDNA andfarnesylated Ras. The Ha-ras and N-ras oligos did not significantly
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comparison with published sequence and sequence from the class II with the novel bicarbonate/lactate two compartment PD fluid of equiv-
alent glucose strength. AGE formation in the standard PD fluid con-positive B cell line Raji revealed a point mutation resulting in a single
amino acid change from phenylalanine to serine at position 961 of the taining 1.36% glucose was comparable to that in the novel PD fluid
containing 3.86% glucose. The daily FGR was greater in the first 5protein. We have subsequently shown that introduction of this muta-
tion into CIITA cDNA abolishes its ability to induce class II expression days of incubation than in the subsequent 15 days. These results are
compatible with the presence of greater amounts of glucose degrada-when transfected into HeLa cells as compared to normal sequence
CIITA cDNA which induces full class II expression in this cell line. tion products in the standard single compartment bag resulting in
enhanced AGE formation. Any effect on AGE formation of the differ-We conclude that this single amino acid change renders CIITA non-
functional, resulting in complete absence of class II expression. ent buffer composition of the two PD fluids remains to be elucidated.
Are quality of life, nutrition and dialysis adequacy similar in AsianPolycystin expression in PKD-1, infantile PKD-1 and TSC-2/PKD-1
cystic tissue: heterogenous expression of the normal allele in cystic and Caucasian patients on Peritoneal Dialysis? A. Bakewell, R. Higgins,
D. Dukes and M. Edmunds, Renal Unit, Walsgravc NHS Trust Hospital,epithelia. A.C.M. Ong, P.C. Harris, S. Rossetti, D.R. Davies1 and C.J.
Ward, MRC Molecular Haematology Unit, Institute of Molecular Medi- Clifford Bridge Road, Walsgrave, Coventry, CV2 2DX, UK. It is impor-
tant to assess if patient perceptions and treatment requirements differcine, University of Oxford, Oxford, UK and 1Dept of Cellular Pathology,
John Radcliffe Hospital, Oxford, UK. The precise mutational mecha- in Asians and Caucasians on Peritoneal Dialysis. All Asian patients
(7F, 20M) treated with peritoneal dialysis for .3 months betweennism responsible for the initation of cyst formation in PKD-1 remains
controversial although recent evidence has been put forward to suggest November 1996 and December 1997 were compared to age matched
Caucasian controls (8F, 19M), 12 diabetics in each group. Postcodesa ‘two-hit’ mechanism. To investigate this possibility further, we have
studied polycystin expression in cystic tissue obtained from patients were converted to electoral wards and then categorised into five levels
of deprivation – Townsend scores. Quality of Life was assessed usingwith defined germline truncating mutations or deletions of PKD-1.
Renal tissue was obtained from 8 patients with adult-onset PKD-1, 1 KDQOL self-administered questionnaire; adequacy of dialysis by total
creatinine clearance/1.73m2/BSA (CrCl); nutrition by protein nitrogenpatient with infantile-onset PKD-1 and 2 patients with a contiguous
deletion involving TSC-2 and PKD-1; cystic liver was also obtained appearance (PNA), prealbumin (preA), albumin (A), and subjective
global assessment (SGA: % mal-nourished). Statistics used were Mannfrom 1 patient with a truncating PKD-1 mutation. Truncation of the
C-terminal epitope from the putative mutant protein allowed us to Whitney U, Spearman rank correlation and chi-squared. Values 5
mean 6 Standard Deviation. Mean age (Asian 49 6 13 vs Caucasiandetect the presence or absence of the normal protein using a mAb to
the extreme C-terminus of polycystin. Significantly, polycystin expres- 48 6 14), length of time on renal replacement therapy, (Asian 26 6
29 months vs Caucasian 28 6 32 months) and months on CAPD (Asiansion was absent in a minority of cysts (,20–30%), in spite of the
normal expression of other marker proteins. Nevertheless, the majority 23 6 18 vs Caucasian 22 6 23) were similar in both groups. Quality
of life was significantly lower in Asians, with particularly low scoresof cysts showed strong polycystin immunoreactivity suggesting that the
normal allele continues to be expressed by most cystic cells. Finally, in questions relating to End Stage Renal Disease (49 6 16 vs 61 6
12); p , 0.01). By Townsend score, Asians were significantly moreimmunoblotting of a PKD-1 kidney carrying a germline truncating
mutation, using a mAb to the N-terminus of polycystin, revealed ex- deprived (p , 0.01).
pression of the normal polycystin protein (460 kDa) but not of a novel
mutant protein. We conclude that cysts probably arise because of a ‘loss
of function’ rather than a ‘gain of function’ mechanism. In addition, if PreA A PNA CrCl SGA
the postulated ‘two-hit’ mechanism is correct, then a high rate of g/l g/l g/day L/wk %
somatic missense mutations must occur to account for cyst initation
Asian 0.3860.08 32 65 58 616* 73 627 52in PKD-1, infantile PKD-1 and TSC-2/PKD-1.
Caucasian 0.3560.1 31 64 74 621 77 636 41
*p , 0.005
Comparison of In Vitro AGE formation between standard PD fluid
and a novel bicarbonate/lactate formulation. D.J. Millar, C. Holmes1, D.
Faict2 and A. Dawnay, Renal Research Laboratory, St. Bartholomew’s There was a high proportion of malnourished patients in both groups
Hospital Medical College, London, UK; Baxter Healthcare, McGaw as demonstrated by subjective global assessment. Quality of life did not
Park1, IL and Nivelles2, Belgium. Peritoneal advanced glycation end- correlate with dialysis adequacy, Townsend Score, or any nutritional
product (AGE) formation may be accelerated by glucose degradation parameter within either group, despite lower Quality of life, Townsend
products produced as a consequence of heat sterilization of PD fluid. Score and PNA in the Asians. Overall, PNA correlated with CrCl (p ,
The formation of these degradation products is reduced if the glucose 0.001). Asians on peritoneal dialysis have a lower quality of life which
is separated from the electrolytes during heat sterilization. This pilot is not solely explained by dialysis adequacy, social deprivation or nutri-
study compared in vitro AGE formation in PD fluid (1.36% and 3.86% tional factors.
glucose) heat sterilized in a two compartment bag (bicarbonate/lactate
buffer) with that in a standard single compartment bag (lactate buffer,
Dianeale). PD fluid pH was adjusted to 7.4 with 50 mM phosphate Effects of glucose dialysate on matrix production by human peritoneal
buffer, 0.1% azide and human serum albumin (HSA, 1 g/l), was added mesothelial cells (HPMC) — the role of TGF-b. J.F. Medcalf, J. Walls
as a model protein, and the solutions incubated at 378C for 0, 5 and and K.P.G. Harris, Department of Nephrology, Leicester General Hos-
20 days. AGE formation was assessed by measuring fluorescence (F) pital, Leicester, U.K. CAPD has a five year technique survival of less
(Ex350/Em430) at each time point and fluorescence generation rate than 50%. Dialysate glucose has been implicated in this peritoneal
(FGR) per day for each time interval. loss. We have previously demonstrated that PD4 decreases cell viability
AGE formation was greater in standard PD fluid (Dianeale) compared due to hyperosmolality, and stimulates release of Fibronectin (FN)1.
To investigate the mechanism HPMC were cultured in 50:50 dialysis
solution and M199 with 0.1% FBS. Dineal PD4 was compared with a
lab manufactured dialysate with the same composition as PD4 but
with glucose concentration varied between 5-40mmol/L (LAB). Exper-F units/g HSA/l FGR per day iments were conducted in the presence and absence of an anti-TGF-b
antibody. FN and TGF-b were measured in the supernatant at 12 hrsDays 0 5 20 0–5 5–20
by ELISA and expressed as % LAB at 5 mmol glucose corrected per
1.36% Standard 68 373 591 61 15 mg total cell protein. In a separate experiment recombinant TGF-b11.36% Novel 69 300 380 46 5 was added to LAB with 5 mmol glucose. Using the same protocol
3.86% Standard 62 767 1322 141 37 HPMC were cultured and mRNA extracted to assess FN gene expres-
3.86% Novel 60 383 671 64 19 sion by Northern analysis. PD4 stimulated an increase in FN (127 6
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15.7%, p , 0.05) and TGF-b (144 6 26.7%, p , 0.05) vs LAB at 5 mmol into low, medium and high risk groups according to age and comorbid
conditions.D-glucose. Exogenous TGF-b produced a dose dependant increase in
fibronectin release over the range 0–1 ng/ml (280 6 45% increase at
TGF-b 1 ng/ml, p , 0.0001). Anti-TGF-b antibody had no effect on
FN release under control conditions (LAB at 5 mmol/l D-glucose). Risk stratification Group 1 Group 2
However, the increase in FN in response to PD4 was significantly
Low 35 (48.6%) 18 (20.2%)reduced by anti-TGF-b antibody to levels not different from control
Medium 24 (33.3%) 43 (48.3%)(98.7 6 5.7%, p , 0.05 vs no Ab). Anti-TGF-b Ab blocked the increase
High 13 (18.1%) 28 (31.5%)in FN seen with exogenous TGF-b upto a TGF-b concentration of
2.5ng/ml. Both PD4 and Exogenous TGF-b resulted in an increase in
FN gene expression (2.4 6 0.6 and 10.0 6 1.8 fold increase vs LAB
at 5 mmol/glucose). These data suggest that the pro-fibrotic effect of Comorbidity is less in group 1 than group 2 (p 5 0.001 Chi-square)
glucose dialysate on HPMC is mediated through stimulation of and follow-up longer (p 5 0.005 Chi-square). There is no significant
TGF-b, which promotes FN gene expression and protein production. difference between the two groups in either age, sex or serum albumin.
1Medcalf, J.F. et al. Renal Assoc. Autumn meeting 1997 The increased mortality reported in patients first dialysed via emer-
gency access may purely be a reflection of increased comorbidity con-
founded by relatively acute presentation for dialysis. Prospective data
are essential to fully assess comorbidity and we are currently conductingProspective epidemiological study of chronic renal failure in children
a prospective study of outcome according to mode of presentation inin Wales. A. Imam, R. Roberts and K. Verrier Jones, Department of
all patients in one year starting chronic dialysis in Scotland.Child Health, University of Wales College of Medicine, Cardiff Royal
Infirmary, Cardiff. A survey of chronic renal failure in Welsh children
was carried out in order to determine the incidence of new cases and
Novel Erythropoiesis Stimulating Protein (NESP) administered subcu-overall prevalence of chronic renal failure (CRF) and end stage renal
taneously (SC) for the treatment of renal anaemia. I. C. Macdougall,disease (ESRD) to plan services for conservative management and
Renal Medicine, King’s College Hospital, KCSMD, London, on behalfrenal replacement therapy. Children under 18 years with an estimated
of the UK NESP Study Group*. NESP is a novel hyperglycosylatedGFR of less than 33% of normal for age and all children with function-
analogue of recombinant human erythropoietin (EPO) which has aning renal transplants were included. Cases were notified via the Welsh
increased terminal half-life in man compared with EPO (MacdougallPaediatric Surveillance Unit. Following notification, questionnaires
et al., JASN 1997; 8: 268A). The aim of this randomised, sequentialwere sent to paediatricians and nephrologists to identify the cause,
dose-escalation study was to investigate the optimal dose and frequencydate of presentation, height, weight and level of creatinine. Other
of SC NESP for the treatment of anaemia in stable CAPD patientscomplementary data sources were used to validate the data. Surveil-
with haemoglobin (Hb) , 10 g/dL. Patients were randomised to receivelance covered a three year period from 1st July 1994 to 30th June
a total weekly dose of NESP administered either once or three times1997. A total of 84 cases of CRF were identified, male:female ratio
weekly (5 patients at each schedule). Up to 6 dose levels were plannedwas 3:1. 34 cases had a functioning transplant and 11 were on dialysis
to be enrolled sequentially. The dose escalation continued until theat the time of notification. The main groups of primary renal disease
rise in Hb over 4 weeks was h 3 g/dL in more than 2/5 patients in thewere reflux nephropathy (30%), congenital hypoplasia/dysplasia
schedule group or a decision was made to stop by the study’s Safety(20%), obstructive uropathy (18%), hereditary disorders (15%) glom-
Monitoring Committee. Patients with h 1g/dL rise in Hb over 4 weekserulopathies (9%) and others (8%). The most common age for diagno-
(responders) were to continue NESP treatment for a further 12 weekssis of CRF was the first year of life and congenital malformation
at the same dose and schedule. Patients who did not respond wereaccounted for the majority of such cases. Using 68 cases with complete
withdrawn, and could be enrolled at higher dose levels. Additionaldata sets the minimum incidence of new cases of chronic renal failure
patients were included in the study at effective dose levels to extendwas 7 per million children per year and prevalence was 95 per million
patient experience.children per year and 19 per million total population. The minimum
incidence of new cases of ESRD was 4 per million children per year
and prevalence of children under 18 years was 48 per million. Our
Weeklyresults were comparable with other European studies. Our prospective
NESP Proportion Change in Hbsurvey has defined the need for planning services for children with
Dose dose of at 4 weeks**CRF. Reflux nephropathy was the most common cause of CRF and
level lg/Kg responders 13/week 33/week g/dLthis is potentially preventable.
1 0.075 0/6 0/3 0/3 0.24 (20.53, 1.01)
2 0.225 2/10 2/5 0/5 0.40 (20.20, 1.00)
Elective access for chronic dialysis: The influence of case-mix. W. 3 0.45 6/10 3/5 3/5 1.08 (0.48, 1.68)
Metcalfe, K. Simpson*, I.H. Khan and A.M. MacLeod, Aberdeen Uni- 4 0.75 15/22 8/11 7/11 1.40 (0.99, 1.81)
versity and Glasgow Royal Infirmary*, Scotland. On behalf of the Scot-
**Mean (95% CI) for all patients in each dose leveltish Renal Registry and Audit System. Funded by the Clinical Resource
and Audit Group of the Scottish Office. Retrospective studies suggest
that patients presenting for first chronic dialysis in whom securing To date there have been 48 exposures to NESP in 37 patients. Of the
access is an emergency procedure have a worse prognosis than those 6 patients who responded at dose level 3, three have since reduced to
in whom permanent access has been achieved electively. We have level 2 (due to Hb . 13g/dL). Of the 15 patients who responded at
prospectively analysed the establishment of dialysis access and burden dose level 4, ten have since reduced to level 3, and six of these have
of comorbid illness in all patients presenting for chronic renal replace- subsequently had dosing temporarily withheld (due to Hb . 13g/dL
ment therapy in Scotland (population 5 million) between 01/10/97 in 5 patients and hypertension in 1 patient). Dose escalation was
and 31/01/98 (n 5 161). Patients were grouped according to mode of stopped at level 4, and only patients who failed to respond at this level
presentation. Group 1 were followed up by a nephrologist and had were given the option to receive higher doses. Reported adverse events
permanent access ready for use by time of first dialysis n 5 72: Mean were similar to those expected during EPO therapy, and no antibodies
age 56.6 years. Range 21–84 SD 14.5, mean period of follow-up 57 to NESP have been detected. These preliminary results suggest that:
months Range 1–456. Group 2 required emergency access and com- (i) NESP is effective for the treatment of renal anaemia, (ii) the optimal
prise those followed up by a nephrologist but with no functional perma- weekly dose appears to be 0.45 lg/Kg, and (iii) there is no apparent
nent access by first dialysis, as well as those presenting with end stage difference between once and three times weekly dosing with NESP,
or with acute renal failure which failed to resolve n 5 89: Mean age which may confer a clinical advantage over EPO.
65.3 years Range 23–87 SD 12.9, mean period of follow-up 18 months *Renal Units of Bristol Southmead Hospital, Cardiff Royal Infirmary,
King’s College Hospital, Leicester General Hospital, Oxford ChurchillRange 0–133. Patients were divided using a previously validated system
Abstracts 2561
Hospital and Manchester Royal Infirmary; Amgen (Cambridge, UK
All N575 Male N545 Female N530and Thousand Oaks, USA)
Univ Multiv Univ Multiv Univ Multiv
r2 r2 r2 r2 r2 r2
Absorption of recombinant human erythropoietin following subcuta-
Triglycerides 38%a 34%a 37%a 27%a 58%a 56%aneous injection in dialysis patients. C.P. Breen, J. Marsden*, G.K.
HL 7%b 3% 21% 7%b 1% 2%James1, G. Chandler and I.C. Macdougall, Departments of *Clinical
LpL 0% 0% 2% 1% 5% 2%Biochemistry, 1Dietetics, and Renal Medicine, King’s College Hospital,
KCSMD, London. It is possible that poor absorption of EPO following ap , 0.001, bp , 0.03
SC injection may be a cause of hyporesponsiveness to the drug, particu-
larly in obese subjects. Although the pharmacokinetics of EPO are
well-characterised, there is a paucity of data on the expected increments
in serum EPO levels following administration of the commonly used had levels of LDLIII (109 6 11 vs 33 6 7 mg/dl, p , 0.001), associated
SC doses. This was the aim of the present study which compared the with increased cardiovascular disease in normal populations. These
trough and peak (18 hour) serum EPO levels following doses of 2,000, results indicate altered regulation of LDLIII levels in ESRF. The lower
4,000 and 10,000 units injected into the upper arm of 32 dialysis patients HL activity in men makes the enzyme more rate limiting than in normal
(26 HD, 6 CAPD), (19 males, 13 females). Body mass index (BMI) subjects, whereas in women due to the overwhelming influence of the
and triceps skin-fold thickness (TSFT) (recorded using Holtein skin- raised TG (2.4 6 0.3 females vs 1.9 6 0.2 males), HL no longer
fold callipers) were also measured. Serum EPO levels were measured contributes. Patients with triglycerides .1.5 mmol/l have atherogenic
using a quantitative ELISA assay and expressed in mU/ml. The results levels of LDLIII.
(mean 6 SD) are shown below.
A prospective crossover study to compare the heparin requirements
of two haemodialysis membranes. M.J. Wright, G. Woodrow, S. Um-Trough to
pleby, S. Hull, J.H. Turney and A.M. Brownjohn, Renal Unit, LeedsEPO Trough Peak EPO peak
General Infirmary, Leeds, UK. Heparin is the most commonly useddose U EPO level level increase Increment
anticoagulant for haemodialysis despite disadvantages including exac-
2,000 erbation of blood loss, thrombocytopaenia, osteoporosis and dyslipi-
(n511) 17.6 (69.1) 36.3 (612.1) 18.6 (613.1) 2.57 (61.29) daemia. Alternatives include epoprostanol, which is expensive and
4,000 may cause hypotension, or frequent saline flushes, which are inconve-
(n59) 24.5 (69.4) 57.3 (623.8) 32.8 (624.1) 2.85 (62.14) nient and represent a considerable additional fluid load to remove
10,000 during treatment. Asahi Biowet membranes (polyethyleneglycol chains
(n512) 48.9 (634.1) 105.0 (655.1) 56.1 (647.7) 5.63 (610.87) grafted onto a cellulose base) have been shown to produce less activa-
tion of the clotting cascade than conventional cuprophane membranes.
We found that the patients attending our satellite unit could be dialysed
As expected, there was a step-wise increase in mean trough and peak on these membranes with no anticoagulant or extra flushes. We sought
EPO levels with increasing EPO dosages, although absorption was to compare the anticoagulant requirements of the Biowet membrane
highly variable. There was a strong negative correlation between the with a cuprophane membrane (Gambro GFE) in a prospective ran-
increase in serum EPO levels and BMI at 10,000 units (r 5 20.781), domised crossover study. 53 patients completed the study (17 women,
and a similar correlation with TSFT (r 5 20.602). This correlation 36 men; mean age 58.4, range 23–79 years). All patients were stable
was lost at lower doses since the EPO levels obtained were close to on dialysis and had arterio-venous access capable of taking two needles.
the physiological range of 9.1 2 30.8 mU/ml (r 5 20.311 for 2,000 Patients were randomised to either the Biowet or cuprophane mem-
units and r 5 0.108 for 4,000 units). These data indicate that absorption brane then heparin administration was progressively reduced to the
of EPO at higher doses is influenced by SC fat distribution and BMI. lowest dose that prevented visible clotting of the membrane in excess
Impaired absorption of EPO was demonstrated in obese patients who of that normally encountered. Patients were dialysed at this minimum
were responding poorly to the drug, and this may be remedied by dose for a month after which heparin requirements and Kt/Vurea were
switching to IV administration in HD patients. compared. This process was then repeated for each patient using the
other membrane. Heparin administration during dialysis was reduced
from a mean of 16.77 (66.21) units/kg/hour to 0.98 (62.03) units/kg/
Regulation of low-density lipoprotein (LDL) subfractions in end-stage hour for the Biowet membrane and 0.94 (61.95) units/kg/hour for the
renal failure (ESRF). C.J. Deighana, M.J. Caslakeb, M. McConnellb, cuprophane membrane (both P , 0.0001 when compared with full
J.M. Boulton-Jonesa and C.J. Packardb, Renal Unita and Department of anticoagulation; no difference between membranes). The mean
Pathological Biochemistryb, Glasgow Royal Infirmary, Glasgow. LDL Kt/Vurea was 1.16 (60.19) with full anticoagulation versus 1.11 (60.21)
exhibits heterogeneity, with small dense LDL (LDLIII d 5 1.045–1.065 using the Biowet and 1.15 (60.19) using the cuprophane dialyser (all
g/ml) associated with increased cardiovascular risk. Patients with ESRF NS). The heparin requirements of those taking aspirin were not signifi-
have hypertriglyceridaemia, low-normal LDL-cholesterol (LDL-C), cantly different to those who did not. At the end of each two month
low HDL-cholesterol (HDL-C) and excess small dense LDL. To de- treatment period 38 patients on the Biowet and 39 patients on the
velop LDLIII normally requires triglycerides .1.5 mmol/l and hepatic cuprophane membrane were dialysing successfully with no heparin
lipase (HL) .15 umolFA/ml/hr. In women triglycerides and HL deter- infused during dialysis and the remainder were using considerably
mine LDLIII mass, but in men only triglycerides are significant. We reduced doses. These results do not support the theory that the coated
investigated regulation of LDL subfractions in ESRF, measuring LDL cellulose membrane has a lower anticoagulant requirement than stan-
profiles, HL and lipoprotein lipase (LpL) activity. (All mean 6 SE). dard cuprophane. This study suggests that dialysis can be performed
In 75 patients, the mean triglyceride was 2.1 6 0.1, LDL-C 3.3 6 0.1 successfully with much smaller anticoagulant doses than are currently
and HDL-C 1.0 6 0.04 (all mmol/l). LpL & HL activity was low (LpL in common use.
3.1 6 0.3, HL 10.3 6 1.1 mmolFA/ml/hr, normal range LpL 2.5-6.7, HL
7.3–23.1 mmolFA/ml/hr). Univ. 5 Univariate, Multiv. 5 multivariate
analysis for regulation of LDLIII: Hepatitis B vaccination in end stage renal disease; results of routine
Triglycerides showed a positive association with LDLIII levels, ac- practice. K. Bel’eed, M. Wright, D. Eadington, M. Farr and L. Sellars,
counting for 27% of the variability in men and 56% in women. HL Department of Renal Medicine, Hull Royal Infirmary, Hull, UK. In
was a determinant of LDLIII levels in men but not women. After January 1996 one of our long-term haemodialysis (HD) patients ac-
adjusting for triglycerides, HL accounted for a further 6% of LDLIII quired acute hepatitis B (HepB) infection by intravenous drug abuse;
variability in all patients (p , 0.05) and 15% in men (p , 0.01). subsequent screening confirmed no transmission within the unit. We
have since offered vaccination against HepB to all patients on chronicHypertriglyceridaemic patients (triglycerides .1.5 mmol/l, N 5 46)
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dialysis (haemodialysis n 5 206, CAPD n 5 84) and pre-dialysis pa- small but significant rise in cholesterol (partially compensated by a
small rise in HDL), and a significant improvement in magnesium. Ittients (n 5 50, mean serum creatinine 520 6 99.6 mmol/l). Recombinant
HepB vaccine (Engerix B, 40 mgm IM) was administered at 0, 1, 2 is feasible to convert patients from Tac to CsA in clinical practice.
and 3 months, with 40 mgm boosters 3 monthly until full seroprotection
(anti-HBs antibody titre . 100 mIU/ml) was obtained. Two hundred
and sixteen patients completed a course of primary vaccination (haemo- Initial management of ARF by non-specialists: a definite need for
improved education. P.E. Stevens, N.A. Tamimi, A.I. Mikhail, M.K.dialysis n 5 142, CAPD n 5 56, pre-dialysis n 5 18). Ninety-nine
patients received a first booster (haemodialysis n 5 67, CAPD n 5 Al-Hasani, D.I. Prosser, and P. Carmichael, Department of Renal Medi-
cine, Kent and Canterbury Hospital, Ethelbert Road, Canterbury, Kent25, pre-dialysis n 5 7) while 13 patients on haemodialysis and 1 CAPD
patient received a second booster. Response rates are summarised; CT1 3NG. Using the Renal Association standards subcommittee defi-
nition of ARF (blood urea $40 mmol/l and/or creatinine $300
mmol/l in a patient with no evidence of pre-existing renal disease) we
have undertaken a 12 month prospective survey of ARF in the EastAnti-HBs antibody response
Kent Health Authority Area. The aim of this study was to evaluate
Anti-HBs the initial management of ARF by non-specialists, and to determine
antibody titre HD CAPD pre-dialysis total what proportion of ARF may be potentially preventable by improved
mIU/ml n (%) n (%) n (%) n (%) education. Patients identified on a daily basis by computer extract were
clinically assessed at the time of identification, and their managementPrimary
was reviewed. Results of the full year evaluation will be presented butvaccination .100 47 (33) 14 (25) 8 (44) 69 (32)
preliminary analysis of the first 6 months data is shown below. 15810–100 44 (31) 20 (36) 4 (22) 68 (31)
patients with ARF were assessed during the first 6 months. The tableAfter 1st
below summarises the initial non-specialist management.booster .100 26 (39) 15 (60) 3 (43) 44 (44)
10–100 14 (21) 4 (16) 2 (29) 20 (20)
After 2nd
booster .100 4 (31) 0 0 4 (29) Investigation/ % of Investigation/ % of
10–100 5 (38) 1 (100) 0 6 (43) intervention patients intervention patients
Urethral catheter 72 Record of urine output 77
Urinary electrolytes 4 CVP line 38Eleven out of nineteen patients achieving full immunity (anti-HBs . Renal ultrasound* 46 Arterial blood gases 26100 mIU/ml) had anti-HBs titres , 100 mIU/ml when tested after one Coagulation studies 37 Urine culture & microscopy 51year. We conclude: i) stringently implemented ‘universal precautions’ Blood cultures 38 C-reactive protein 15do prevent transmission of hepatitis B infection, ii) 32% of patients
* or other radiological assessment of the kidneysachieved seroprotection (anti-HBs . 100 mIU/ml) after a primary
course of vaccination, and a further 44% of patients achieved seropro-
tection after a single booster dose of HepB vaccine, iii) vaccine uptake
ARF was judged to have been preventable where there was a directis restricted by patient refusal and logistic problems, iv) antibody titres
relation between an intervention, or lack of intervention, and thedecline faster than anticipated. Although hepatitis B vaccination is
subsequent development of ARF. In 30 episodes ARF was preventable,recommended for patients with ESRD, we suggest that cost-effective-
7 of whom did not survive to leave hospital. The initial non-specialistness and resource issues merit further discussion.
management of ARF is poor. A significant proportion of ARF in
this study could have been prevented by improved education and
understanding of the pathogenesis of ARF.Elective Conversion from Tacrolimus to Cyclosporin—Safety and Met-
abolic Outcome. R.M. Higgins, P. Hart, F.T. Lam and H. Kashi, Renal
Unit, Walsgrave Hospitals NHS Trust, Clifford Bridge Road, Coventry,
Angiotensin converting enzyme inhibitors (ACE-I) and bilateral ne-CV2 2DX. Conversion from tacrolimus (Tac) to Cyclosporin (CsA)
phrectomy in the treatment of hypertension in non-diarrhoeal haemo-has previously been reported, but only as indicated by rejection or
lytic uraemic syndrome (d-HUS)—a retrospective study. P. War-adverse effects. Elective conversion has not previously been reported.
wicker1, G. Neild2 and T.H.J. Goodship1, Dept. Medicine, University ofWe have electively converted 19 patients from Tac to CsA, at 3–6
Newcastle upon Tyne1 Division Nephrology, University College Londonmonths after transplantation. Previous serious acute rejection was an
Hospitals2. A prominent feature of d-HUS is renin driven hypertension,exclusion. Cyclosporin was given at 5 mg/kg/day, adjusted to levels of
thought to be secondary to ’pre-glomerular’ arteriolopathy character-150–250 ng/ml. There was no acute rejection in the first 3 months after
ised by severe intimal proliferation and luminal stenosis. ACE-I haveconversion. Subsequently, one patient has been converted back to Tac
been shown to decrease the mortality of scleroderma renal crisis—afollowing rejection, and another for hirsutism. Fasting biochemistry
situation histopathologically, haematologically and clinically similar towas measured on 3 occasions before and after conversion, and the
HUS. In this study we have retrospectively analysed the case historiesmean used for comparisons (group statistics; median and range, Mann
of 32 adults with d-HUS and 109 patients with familial HUS (includingWhitney testing):
published cases) with special reference to the use of ACE-I. In sporadic
HUS hypertension was a common feature (69%) and associated with
an increased mortality (27% vs 10% in the non hypertensive patientsOn Tac On CsA P
{N/S}). Those hypertensive patients treated with ACE-I had a lower
mortality than those treated with standard antihypertensives (10%Creatinine umol /l 138 (95–187) 142 (94–195) NS
Urate mmol /l 348 (237–523) 355 (267–589) NS [1/10] vs 45% [5/11]{p 5 0.09}). In familial HUS hypertension was
more common and often more severe, found in 74% of autosomalMagnesium mmol /l 0.73 (0.63–0.97) 0.82 (0.65–1) 0.037
HbA1c % 5.4 (4.2–9.2) 5.2 (4.3–10.1) NS dominantly and 40% of autosomal recessively inherited HUS. The
Cholesterol mmol /l 5.2 (3.4–6.8) 5.5 (3.8–7.6) 0.033 mortality (defined as death by the time of publication or 1 year mortal-
HDL mmol /l 1.4 (1–1.7) 1.5 (1–2.3) NS ity) of hypertensive patients treated with standard antihypertensives
Chol/HDL ratio 3.47 (2.59–6.4) 3.93 (2.57–6.25) NS (or when none was specified) was 84% (40/49), whereas in a small
Triglycerides mmol /l 1.6 (0.8–3.3) 1.9 (0.6–3.6) NS group of patients (5) receiving ACE-I, and interestingly 11 patients
who underwent bilateral nephrectomy the mortality was 0% {p ,
0.001}. We would recommend that hypertension in the context of HUS
(particularly familial HUS) is treated aggressively with considerationElective conversion from Tac to CsA was not associated with early
given to the use of ACE-I and in those patients not responding torejection, and renal function was stable at 3 months post conversion.
Changes in lipid profiles were small in magnitude, but there was a standard treatment, bilateral nephrectomy. The risk of renal loss with
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ACE-I or the finality of bilateral nephrectomy must be weighed against Seven patients had active disease at the introduction of MMF (3 sero-
logical evidence, 4 serological and clinical evidence). Three patientsthe very small odds of renal recovery in the inherited form of HUS—
only 11% in autosomal dominant HUS (6/55) and 27% in the first were in remission on starting MMF but 2/3 had previously relapsed
on combined treatment with Azathioprine and Prednisolone and hadepisode of autosomal recessive HUS (12/44) in our survey.
recently completed pulsed Cyclophosphamide therapy (6 3 monthly
pulses 5–10 mg/kg). Six out of 10 were treated with MMF and Predniso-
lone, 3/10 with MMF alone and 1/10 with MMF, Prednisolone andThe control of acidosis—short vs. long haemodialysis. G.H. Hartley,
T.H.J. Goodship, N.A. Hoenich and J.S. Tapson, Department of Medi- Cyclosporine. All the patients tolerated MMF without leucopaenia or
withdrawal due to gastrointestinal side effects. One patient relapsedcine, University of Newcastle upon Tyne. An important function of the
treatment of chronic renal by dialysis is correction of acidosis. It has after 16 months treatment with MMF (MMF 1 g b.d. and Prednisolone
5 mg o.d.). Double stranded DNA antibodies (dsDNA) were un-been reported that reducing dialysis treatment time can impair ade-
quate repletion of the bicarbonate buffering system. To investigate changed in 7/10 and fell in 3/10. Complement levels (C3 and C4) rose
in 2/10 patients. There were no significant changes in proteinuria orthe effect of treatment duration on the control of acidosis, we examined
total CO2 (TCO2) repletion during both short (#150 min) and long renal function. Our preliminary results from a heterogeneous patient
group suggests that MMF may have a place in the management of($240 min.) dialysis.
long-standing or resistant lupus nephritis.
Angiotensin-Converting Enzyme (ACE) gene polymorphism in Sclero-
derma Renal Crisis (SRC). M. Harber, G. Fanning*, K. Welsh* and
Aine Burns, Centre of Nephrology, Royal Free Hospital, London, NW3
2QG and *Dept. of Transplantation, Churchill Hospital, Oxford. SRC
occurs in approximately 10% of patients with diffuse systemic sclerosis.
In 1990 Rigat et al demonstrated a major Deletion/Insertion polymor-
phism in intron 16 of the ACE gene which accounted for almost 50%
of the variation in serum and tissue levels of ACE, higher levels being
found with the deletion polymorphism. Since then several studies have
shown ACE genotype influences the rate of progression of some renal
diseases, notably diabetic nephropathy and IgA nephropathy. As there
has been a dramatic improvement in mortality with the introduction
of angiotensin-converting enzyme inhibitors (ACEIs) and the renin-
angiotensin system is thought to play a role in the pathogenesis of
SRC we hypothesised that there would be an excess of the Deletion
allele in patients with SRC. DNA was analysed for ACE-gene polymor-
phism by PCR in 38 patients with SRC from 1991–1997 (35 biopsy-
proven) (28 female 10 male), 193 patients with systemic sclerosis but
no history of SRC, and 90 Oxford controls from cadaver donors. The
frequencies of the DD, DI and II geneotypes were 14:20:4, 48:100:45Paired studies were undertaken in 11 patients. TCO2 repletion during
and 28:48:14 for SRC, systemic sclerosis and Oxford control groupshaemodialysis was calculated by directly determining the difference
respectively. There was a statistically significant excess of the Deletionin the TCO2 content of fresh and used dialysate. Using urea kinetic
allele in the SRC group (p 5 0.03) (Chi-square test) but no statisticallymodelling (UKM) to prescribe dialysis, solute clearance was main-
significant difference between the Oxford control group and patientstained constant within patients. This was achieved by using small (1.0
with SRC. The polymorphism distribution in the systemic sclerosism2) and large (1.8 m2) surface area dialysers, standard (500 ml/min)
group was consistent with the Hardy-Weinberg equilibrium, althoughand high (1000 ml/min) dialysate flow rates in short and long dialysis
there was a higher than expected D:I ratio in the Oxford control grouprespectively; and by varying blood flow rates. The graph shows that
(which may represent a selection bias based on increased cardiovascu-TCO2 repletion during short treatment was significantly greater (short,
lar disease in this group). In Summary, in this study, SRC is associated133.9 6 25.9 vs. long, 62.4 6 20.0 mmol, mean 6 SEM, p , 0.05). In
with an excess of the ACE gene Deletion allele.addition, over a 3 month period, no significant difference between
short and long dialysis was seen in pre-dialysis blood TCO2 levels (short,
21.4 6 0.7 vs. long, 22.4 6 0.5 mmol/l, mean 6 SEM). This data suggests
Audit of hospital haemodialysis delivery. N.A. Hoenich1, C. Pearce2,that, providing measures are taken to ensure the sufficient delivery and
T.H.J. Goodship1 and M.K. Ward2, 1Department of Nephrology, 2Renalexchange of bicarbonate, short dialysis can provide adequate control of
Unit, Royal Victoria Infirmary, and University of Newcastle upon Tyne.acidosis.
An audit of the amount of haemodialysis delivered relative to the
Second Edition of the Renal Association standards over a twelve
month period (January 1997-January 1998) has been undertaken usingThe effective use of Mycophenolate Mofetil in the treatment of lupus
both urea reduction ratio (URR) and single pool kinetic modellingnephritis. E.J. Kingdon, E. Psimenou, P. Sweny and A. Burns, Centre
(Pack-H, Fresenius) in patients dialysing three times weekly in a hospi-For Nephrology, Royal Free Hospital School of Medicine, Rowland
tal renal unit. The patients mean age was 56.1 years (range 18–84Hill Street, London NW3 2PF. Mycophenolate mofetil (MMF) has
been demonstrated to reduce the incidence of early graft rejection years), with arteriovenous fistula (28 patients), single lumen atrial
catheter (9), double lumen neckline (11) and PTFE graft (5) beingafter renal transplantation and has been used in rheumatoid arthritis
and other immunologically mediated diseases. MMF limits renal dam- used as access. Seventeen of the patients (32%) were routinely dialysing
with a single needle. The delivered therapy was reviewed over the firstage in a mouse model of lupus nephritis. We embarked on a pilot
study to assess the efficacy and tolerance of MMF in a population of six months of the audit period. The median blood flow was 200 ml/
min (100–375), 26.5% (23–34%) of patients achieved a URR.65%,patients with difficult lupus nephritis. The patients had either relapsed
on conventional treatment or we wished to minimise steroid dose and in contrast, 61% of the patients achieved a Kt/V.1.2. During the
second six months a standardised post dialysis sampling techniquecytotoxic use because of the consequences of previous immunosuppres-
sion. We treated 10 female patients with biopsy proven lupus nephritis was introduced. This increased the number of patients attaining the
standard to 42% (URR) and 66% (Kt/V). For all patients dialysing(3 with SLE/Scleroderma overlap) for a minimum of 3 months with
MMF (Initial dose 1 g/day increasing to 2 g/day). Six patients were at a blood flow of 200 ml/min except those with atrial catheters an
increase to 250 ml/min was implemented. Operational constraints, pre-treated for at least 6 months. Three patients had isolated membranous
nephropathy, 2 had membranous nephropathy with superimposed pro- vented the increase of treatment times which remained at a median
of 240 min (160–400 min). Audit of the blood flow rate showed thatliferative changes and 5 had diffuse proliferative glomerulonephritis.
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the attained median blood flow for the double lumen and single needle gram-negative (G2) or mixed G1 and G2 organisms. 17 of the 20
Gram-positive infections were treated successfully with the above regi-fistula groups was 208 ml/min, whilst for the two needle fistula group
was 236 ml/min. We conclude, that the standardisation of post dialysis men (6 Staph epidermidis, 5 culture negative, 3 Staph aureus, 2 Strept
viridans and 1 diphtheroid); the other 3 (Strept viridans [2] and pneu-sampling leads to an improvement in the amount of dialysis delivered
but vascular access and operational constraints are the principal lim- mococcus [1]) required vancomycin. 1 patient died during treatment
(mixed organisms due to diverticular abcess), and two catheters wereiting factors. The discrepancy between the two methods of monitoring
delivered therapy highlights their non equivalence. The improved dial- removed (1 pseudomonas, 1 Strep viridans with endocarditis). Only 2
of the 18 surviving patients with catheters suffered a relapse of infectionysis delivered, failed to ameliorate pre dialysis phosphate levels, with
less than 40% of patients achieving 1.2–1.7 mmol/l pre dialysis during within 4 weeks of treatment. No case of Clostridium difficile diarrhoea
developed during or following treatment. These results compared fa-the 12 month period.
vourably with historical controls treated prior to May 1997 with a
vancomycin-based regime (6/23 catheters removed and 4 relapses),
and suggest that a once daily cephazolin-based regime is effective andThe Prognosis of Chronic Glomerulonephritis(CGN). C.M. Stirling, K.
Simpson and J.M. Boulton-Jones, Renal Unit, Glasgow Royal Infirmary, safe.
1. Keane WF et al. Perit Dial Int 1996; 16:557.UK. We analysed retrospectively 185 patients (128 male, 57 female)
with biopsy proven CGN presenting to the renal unit in Glasgow
Royal Infirmary since 1986. Patients with a diagnosis of either IgA
nephropathy, membranous nephropathy, mesangiocapillary glomeru- Can the Renal Association Standards be achieved? A. Palmer, T.
Cairns, N. Hakim, A. Lawrence, C. Toogood, and D. Taube, The Renallonephritis (MCGN), mesangioproliferative glomerulonephritis or fo-
cal segmental glomerulosclerosis (FSGS) were included. IgA and mem- and Transplant Unit, St. Mary’s Hospital, London. The coincidental
publication of the 1st edition of the Renal Association’s Standardsbranous nephropathy were the largest groups accounting for 40% and
28% of the total respectively. The median values at biopsy were: age document, Purchaser pressure and the designation of a consultant
nephrologist with a special remit to monitor and audit quality and45.6 years, creatinine clearance 69 ml/min, proteinuria 2.85 g/day, mean
arterial pressure 100 mm Hg and cholesterol 6.6 mmol/l and median outcomes in our unit occurred in spring 1995. We decided to focus on
dialysis adequacy [KT/V; single pool UKM] and % of patients withfollow up post biopsy was 40 months (range 2–139). Twenty two pa-
tients went on to renal replacement therapy and 24 patients died during haemoglobins .10 g/dl in our haemodialysis population, dialysis ade-
quacy [total weekly creatinine clearance], % of patients with haemoglo-follow up. Survival analysis was performed using the Kaplan-Meier
technique with end points defined as end stage renal failure or death. bin .10 g/dl and peritonitis rates in our CAPD population and patient
and graft survivals in our transplant patients. We chose these parame-Five and 10 year survival for the whole group was 81% and 72%.
Further analysis showed that patients with proteinuria .3 g/day at ters because we thought they were the most likely to affect patient
survival and quality of life. The table below shows the results in ourbiopsy had a significantly worse prognosis compared to those with
lesser proteinuria (p 5 0.001) with 5 year survival of 70% compared dialysis programme at 6 monthly intervals with a baseline of April
1995.with 91%. Males had a worse 5 year survival than females (79% v
87%) but this did not reach statistical significance. Survival figures for
the different categories of CGN are given in the table below. Renal
diagnosis had no significant affect on prognosis. Haemodialysis CAPD
% Hb % KT/V % Hb % creat. Cl. Peritonitis rate
.10 g/dl .1.0* .10 g/dl .50 l/wk** episodes/pt mth
Number of 5 year Number
April ’95 24 64 1:17Diagnosis patients survival at risk
June ’95 50 63 1:22
IgA 72 79% 31 Dec ’95 67 72 1:19
Membranous 50 90% 25 June ’96 70 96 74 1:16
MCGN 12 43%* 2 Dec ’96 76 95 97 84 1:16
Mesangioproliferative 20 88% 3 June ’97 71 94 90 97 1:29
FSGS 25 74% 2 Dec ’97 84 100 92 90 1:23
* 4 year survival * Patients dialysed in the main unit and routinely measured after spring 1996
** Only routinely measured after autumn 1996
Our results confirm the importance of proteinuria as a prognostic
factor in CGN and survival analysis suggests an overall improvement The improvement in peritonitis rates in our CAPD patients in winter
compared to historical controls. 1996 followed the reappraisal of our programme and the opening of
our 3rd satellite haemodialysis unit. FK 506 was introduced into our
unit as the primary immunosuppressive agent for renal transplantation
Effective treatment of peritoneal dialysis peritonitis using a vancomy- in summer 1995. Prior to this our actuarial patient and graft survival
cin-free regime. L.C. Goldberg, M. Cleminger, B. Azadian and E. on a standard triple therapy cyclosporin/azathioprine/steroid regime
Brown, Charing Cross Hospital, London W6. Excessive use of vanco- was 97% and 83% at 1 year, 96% and 80% at 2 years respectively.
mycin is associated with the development of multi-resistant organisms, Following the introduction of FK506 our patient and graft survival
especially enterococci, and risks the emergence of vancomycin-resis- was 98% and 93% at 1 year and 98% and 91% at 2 years respectively.
tant Staphylococcus aureus. As a result the International Society for Our unit prices [and overspend] for haemodialysis, CAPD and trans-
Peritoneal Dialysis has recommended that patients are initially treated plantation have not changed appreciably over this period of time.
with both cefazolin in every PD bag and once daily gentamicin IP until However we have had a significant increase in our haemodialysis pro-
an organism is identified1. Such a regime is likely to prove difficult in gramme from 58 to 86 stations.
practice, therefore a more practical regime commencing with once
daily cefazolin (1.5 g) and gentamicin (60 mg) was evaluated in all 21
patients (23 episodes) who developed a new (non-recurrent) episode An audit of the use of the hypochromic index (HI) to prompt prescrip-
of PD peritonitis over a six month period (May-October 1997). Epi- tion of intravenous iron dextran (IID) in haemodialysis patients. H.E.
sodes of Staph epidermidis and culture negative peritonitis were treated Paynter, A.J. Williams and R.A. Banks, Department of Renal Medicine,
with 14 days of cefazolin once daily IP, or 7 days of cefazolin IP then Gloucestershire Royal Hospital, Gloucestershire, U.K. We audited the
7 days of oral cephalexin. Staph aureus infections were treated with use of the HI and IID administration on our haemodialysis unit over
21 days of cefazolin IP and with oral rifampicin. All other growths a 21 month period, to investigate whether the HI was adding to our
were treated according to the organism’s sensitivities. 20/23 infections management. 83 chronic haemodialysis patients were included. Patients
with a ferritin , 200 mg/l or a HI . 10% receive 10 3 100 mg IIDwere due to gram positive (G1) organisms, the remaining 3 due to
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on consecutive dialyses. The HI and Hb are measured monthly, and test. (**p , 0.001 for control v pre-dialysis; #p , 0.01, ##p , 0.001
for pre-v post-dialysis)the serum ferritin three monthly. 68 patients were on erythropoietin,
and 84 courses of 1g IID were given. After excluding patients not
on erythropoietin, those receiving blood transfusions, and those with
another cause for anaemia, the patients receiving iron could be subdi- Control Pre-dialysis Post-dialysis
vided as follows:
QTc maximum (ms) 416.9617.4 480.1 635.4** 496.9 642.9##
QT dispersion (ms) 35.9613.7 63.1 620.6** 76.6 627.0#
QTc dispersion (ms) 41.2611.5 75.9 625.3** 91.0 629.7#
Ferritin group Cornell (mV ) 13.7 64.7 22.7 69.6** 24.7 610.3#HI group( ferritin , 200 lg/l )
( ferritin . 200 lg/l )
“F1”: HI , 10% “F2”: HI . 10% HI . 10%
The results demonstrate that QTc max and QT dispersion are elevated
23 21 15 in haemodialysis patients, and rise post-dialysis to levels comparable
to those seen following myocardial infarction. This may provide a
possible underlying mechanism to explain the high risk of sudden death
in this population.Thus patients in the ferritin group received iron irrespective of the
HI. We compared this group with those in whom the HI had directly
influenced management. Patients in the ferritin group demonstrated
a median rise in haemoglobin (Hb) from 9.5 to 10.5 g/dl at two months Audit of Renal Association target for haemoglobin in Dorset. J.E.
(p 5 0.003). The range of the Hb change was 21.9 to 12.6 g/dl. Taylor, L. Tourgout, D. Sarioglu, Michelle Smith, Angela Ridge and
However, in the HI group, the median Hb rise from 8.5 to 9.4 g/dl K. Yardley, Renal Unit, Dorset County Hospital, Dorchester, Dorset,
was not significant (p 5 0.44), range of Hb change 22.1 to 12.3 g/dl. UK. The Renal Association recommends a target haemoglobin concen-
We subdivided the ferritin group to investigate whether the HI was tration of not less than 10 g/dl in more than 85% of patients after 3
predictive of the Hb rise in these patients. We also subdivided the HI months on dialysis. Our Unit has adopted a policy of Unit-based rather
group into responders whose haemoglobin rose by 1 g in two months, than GP prescribing of Erythropoietin (EPO), and has opted for intra-
and non-responders. The ferritins of these two subgroups were com- venous rather than oral iron replacement in patients receiving EPO.
Out of 117 patients on the dialysis programme, 109 (63 haemodialysispared. The results of both analyses are shown below.
and 46 CAPD) patients have been stable on dialysis for more than 3
months. Of these stable patients, 94 (86%) have achieved a haemoglo-
bin of 10.0 g/dl or above (median haemoglobin: 11.1 g/dl, interquartile
Median Hb change (g/dl ) Median ferritin (lg/l ) 10.4–12.1 g/dl, range 8.0–15.7 g/dl). Eighty-five (78%) patients were
receiving EPO, with a median dose of 6000 iu/week (interquartileP P
4000–6000 iu/week, range 2000–18,000 iu/week). Of the 15 patients
F1 1.061.1 0.54 Responders 5206338 0.59 failing to reach target haemoglobin (12 on EPO), 4 patients had sepsis
F2 1.060.7 Non-responders 3546286 (all on EPO), 1 patient had gastrointestinal bleeding (on EPO), and
1 patient was found to have carcinomatosis (on EPO). In the haemodi-
alysis group (n 5 63), 52 (83%) patients achieved target haemoglobin
(median haemoglobin: 11.0 g/dl, interquartile 10.3–12.2 g/dl, rangeIn conclusion, the hypochromic index in our hands does not contribute
8.1–14.0 g/dl). Of these patients, 58 (92%) were on EPO, with a medianto our management of patients, particularly in regard to the prescrip-
dose of 6000 iu/week (interquartile 4000–8000 iu/week, range 2000–tion of IID. Patients treated with IID on the basis of the HI did
18,000 iu/week). Forty-two patients (41 on EPO) were receiving regularnot demonstrate a significant increase in haemoglobin at 2 months.
intravenous iron, using the ferrous gluconate preparation at a medianSubgroup analysis suggests that the HI is not a predictor of Hb rise
dose of 62.5 mg post dialysis once a fortnight to maintain serum ferritinin patients with a low serum ferritin. We noted wide variability in the
levels in the range 300 – 600 Fg/l. In the CAPD group (n 5 46), 42hypochromic index, and suspect that storage and delay in processing
(91%) patients reached target haemoglobin (median haemoglobin:the blood samples are affecting the reliability of the assay. This poten-
11.1 g/dl, interquartile 10.5–11.8 g/dl, range 8.0–15.7 g/dl). Of thesetial pitfall in the use of the hypochromic index could have important
patients, 27 (59%) were on EPO, with a median dose of 6000 iu/therapeutic implications.
week (interquartile 4000–6000 iu/week, range 2000–6000 iu/week). On
average, 2 patients per month required a total dose iron saccharate
infusion (300 mg or 500 mg according to weight) to maintain serum
ferritin levels above 200 mg/l. Factors which may have contributed to
ECG changes associated with haemodialysis: focus on the QT interval. the achievement of Renal Association target haemoglobin standards
S.T.W. Morris, G.A. Stewart, E. Galiatsou, R.S.C. Rodger, A.G. Jardine, in our Unit include: a) Unit-based rather than GP prescribing of EPO;
Renal Unit and Dept. of Medicine & Therapeutics, Western Infirmary, b) universal use of intravenous iron replacement; c) patient choice of
Glasgow, U.K. Haemodialysis patients die prematurely and most com- dialysis modality; d) 100% use of disconnect systems in CAPD patients
with low peritonitis rates (1 in 67 patient months).monly of cardiovascular causes, with cardiac arrhythmias and unex-
plained sudden death accounting for a substantial proportion of all
deaths. Underlying mechanisms are unclear, although Holter monitor-
ing has revealed frequent ventricular premature beats during and im-
Histopathological predictors of outcome following acute renal allograftmediately post-dialysis. In patients with cardiac failure and following rejection. F.I. Macdonald, N.R. Parrott, C.D. Short, S. Ashraf, P.A.
myocardial infarction, elevated QT dispersion on the standard 12 lead Dyer and I.S.D. Roberts, Renal Transplant Unit, The Royal Infirmary,
ECG reflects non-homogeneous ventricular repolarisation and is asso- Manchester. The Banff classification of renal allograft rejection grades
ciated with cardiac death. This parameter has not previously been acute tubulointerstitial rejection (AIR) by severity of tubulitis and
assessed in patients with renal failure. We recorded ECGs pre- and acute vascular rejection (AVR) by severity of arteritis. The severity
post-dialysis in 50 patients with chronic renal failure and in 20 healthy of tubulitis has not, however, been demonstrated to be of prognostic
controls of a similar age and sex distribution. ECGs were analysed value and other histological features such as glomerulitis and eosinophil
blindly using a digitser and QT intervals were measured and corrected infiltration are of uncertain significance. In order to determine the
for heart rate using Bazett’s formula. QT dispersion was calculated as clinical value of this classification, we have correlated Banff criteria
maximum 2 minimum QT interval. In addition we measured the Cornell with outcome in 134 graft recipients transplanted over 3 years (1994–6)
voltage (RaVL plus SV3), a marker of left ventricular hypertrophy. who suffered at least one biopsy-confirmed acute rejection. Using Banff
criteria, 175 biopsies were suitable for grading from 197 performedResults are expressed as mean 6 sd, and comparison is by student t
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for the diagnosis of rejection. Tissue eosinophil counts were available regeneration through inducing apoptosis of myoblasts. L6 rat myoblasts
for 101 biopsies. Clinical severity of rejection was classified as mild were cultured in serum-free MEM and exposed to acid (pH 7.1) or
(fully responsive to pulse steroid therapy), moderate (partially steroid control pH (7.5) with or without Dexamethasone (DEX) (1.9 ng/ml).
responsive) and severe (requiring ATG therapy). Clinical severity of Apoptosis was detected microscopically by staining DNA with fluores-
rejection correlated with the presence of arteritis (v1/2) but not severity cent bisbenzamide dye, revealing nuclear fragmentation and chromatin
of tubulitis (t2 vs t3; Table 1). Graft failure ensued in 19 of 62 patients clumping. Results are expressed as median % of apoptotic cells per high
with AVR compared to 9 of 63 patients with AIR (p , 0.05). The power field (with interquartile ranges in brackets) for 5 experiments. In
presence of glomerulitis showed no correlation with clinical severity acidified medium alone, apoptotic cells were readily detected (12.3%
or graft loss. Tissue eosinophilia (defined as .10 eosinophils/mm2) was ([6.1–17.5%]) but this was significantly reduced in the presence of
present in 18 of 33 patients who had at least one episode of AVR (v1/ DEX (7.1% ([3.8–11.1%]) (P , 0.05). A combination of DEX and
2), compared to 11 of 45 patients who suffered only AIR (p , 0.02). elevation of pH also significantly reduced apoptosis (3.7% ([0.1–
10.9%]) (P , 0.05). However, while elevation of pH alone had some
tendency to reduce apoptosis (7.5% [1.2–16.1%]), this fell just short
of statistical significance (P , 0.07). These data suggest that apoptosisBanff grade vs. clinical severity (P # 0.05 )
is a significant factor affecting myoblast number in vitro and that
Banff 93 grade glucocorticoid is a potent suppressor of this effect, contrary to its actionClinical
on lymphocytes. This implies that glucocorticoid could have beneficialseverity I: t2v0 IIA: t3v0 IIB: v1/2
effects on muscle regeneration in uraemia in addition to its better
Mild 40 15 36 characterised role in promoting protein wasting.
Moderate 12 5 18
Severe 3 1 14
Renal pathology findings in plasma cell dyscrasias. A clinico-pathologi-
We conclude that arteritis but not severe tubulitis or glomerulitis is cal review. R. Barnes, F. Moro-Azuela, P. Bass, J.R.D. Dathan and M.
an adverse prognostic factor in acute rejection. Tissue eosinophilia is Rogerson, Department of Pathology and Division of Medicine, South-
associated with vascular rejection. Our findings support the 1997 revi- ampton University Hospirals, UK. The renal involvement in plasma
sion of the Banff classification, replacing grades with types of acute cell dyscratias (PCD) is very variable. We retrieved the spectrum of
rejection. renal biopsy findings in patients with known PCD and/or serum/urine
paraproteins. The aim of the study was to correlate biopsy findings with
presentation and prognosis. Renal records at Southampton University
Hospitals were searched over the time period 1977–1996 and patients
TGFb suppressed macrophages mediate mesangial cell matrix degra- with a diagnosis of PCD and/or serum/urinary paraprotein retrieved.
dation. I.Z.A. Pawluczyk and K.P.G. Harris, Department of Nephrol- Patients notes, reports, slides and electron microscopy material were
ogy, Leicester General Hospital, Leicester, UK. IL-4, IL-10, IL-13 and retrieved and reviewed. Bone aspirates and trephine reports were also
TGFb are cytokines known to have suppressive effects on macrophage reviewed. 43 patients (32 male, 11 female) were identified, the meanfunction. We have previously reported that TGFb pretreated macro- age at biopsy was 64 years (range 35–84), 38 patients had evidence ofphages have a reduced ability to induce fibronectin accumulation by rat a paraprotein (18 had an IgG paraprotein, 10 light chains only). Fivemesangial cells compared to non treated macrophages [KI 52:262,1997]. patients had no serum/urinary paraprotein. 61% of patients presentedThe current study aimed to investigate the mechanism underlying with renal impairment (serum creatinine greater than 125 umol/l). 16this observation. Confluent, quiescent mesangial cells were exposed to
patients showed an unusual tubulo-interstitial or glomerular immuneconditioned media derived from elicited, LPS stimulated macrophages
complex disease and 8 had AL amyloid. In general, all renal lesions(MPCM) or macrophages having been pretreated with 25 ng/ml TGFb
were associated with poor outcome and the bone marrow biopsy/(MPCMTGF). Northern blot analysis was utilised to probe for the expres- trephine evaluations were equivocal in many cases. Despite advancedsion of genes for fibronectin, the matrix metalloproteinase transin and
serological/immunological methods for detecting paraproteins/PCD,its inhibitor TIMP-1, and the universal modulator of matrix accumula-
renal biopsy remains a mainstay in suggesting diagnosis and a negativetion TGFb. RNA was extracted from mesangial cells following 24 hr
bone marrow does not rule out a PCD.exposure to the conditioned media. Mesangial cell fibronectin mRNA
levels were only slightly, though significantly, reduced by 12.3 6 3.3%
in response to MPCMTGF (p , 0.009 vs MPCM, n 5 6). However,
MPCMTGF induced a dramatic 129 6 47% increase in transin mRNA Sensitivity of lymphocytes from renal transplant patients to Cyclo-
levels (p 5 0.03 vs MPCM, n 5 4), while TIMP-1 gene expression, sporin A and Tacrolimus. M.P. Delaney, E. Smythe, 1R.M. Higgins
under the same conditions, was only increased by 43.0 6 9.9% (p 5 and A. Morris, Dept. of Biological Sciences, University of Warwick,
0.002 vs MPCM, n 5 5). In contrast, TGFb gene transcription was Coventry, UK, and 1Renal Unit, Walsgrave Hospital, Coventry, UK.
significantly reduced by 35.4 6 7.8% by MPCMTGF (p , 0.04 vs MPCM, Cyclosporin A (CyA) and Tacrolimus (Tac) immunosuppress through
n 5 5). These data indicate that reduced fibronectin levels in response inhibiting T-cell proliferation and form the basis of modern transplant
to MPCMTGF are largely due to increased expression of transin and drug regimes. The aim of this study was to establish the range oftherefore increased matrix degradation. Reduced expression of TGFb, sensitivity of T cells from individual patients to these drugs and anyknown to modulate transin expression via an inhibitory element in the correlation with clinical parameters. Since Tac has been widely used fortransin gene promoter, is likely to contribute to this effect. A smaller CyA ‘failure’, we wished to see if patients exposed to CyA developedeffect on fibronectin synthesis may also play a role. In conclusion, by specific drug resistance. Peripheral blood mononuclear cells preparedsuppressing macrophage-induced matrix accumulation, TGFb could
from 38 renal transplant patients were stimulated with Con A in thehave a potentially useful role in allowing recovery from macrophage-
presence of either CyA (1–300 mg/li) or Tac (0.03–10 mg/li): incorpora-induced glomerular injury.
tion of 3H-thymidine was used as a measure of T cell activation. In 33
patients maximum inhibition was about 90% and a drug dose for 50%
inhibition (ID50) could be established. The mean ID50 for CyA was
29.3 mg/li (SD 25, range 1.5–60) and for Tac was 1.2 mg/li (SD 1.9,Dexamethasone decreases apoptosis in L6 myoblasts. W. Pickering,
range 0.08–5.5). The sensitivities of lymphocytes to the two drugs wereA. Bevington and J. Walls, Dept. of Nephrology, Leicester General
correlated (p 5 0.0001) and the ratio of the mean sensitivities was 24.Hospital, Leicester, UK. Skeletal muscle wasting in uraemia is associ-
Mean trough blood levels of the two drugs were 230 mg/li (SD 190,ated with loss of muscle fibres (Clyne et al Nephron 63, 395 (1993) as
range 117–346) for CyA and 14.3 mg/li (SD 4.6, range 8.6–24.6) forwell as fibre atrophy. In principle fibre regeneration could occur
Tac. Sensitivity was independent of time post transplant, whether CyAthrough differentiation of myoblast-like satellite cells. The aim of the
or Tac was used, and whether steroids were given. There was nopresent study was to determine whether catabolic stimuli known to
promote muscle wasting (acidosis and glucocorticoid) could prevent correlation between incidence of acute rejection and ID50.
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The Renal Registry and variation in measurement of biochemical re-
Populationsults at different laboratories. D. Ansell, D. Newman, H. Taylor, E.
Completed (Ms) In progressWill and the Renal Registry subcommittee. Nephrologists have been
aware of variations in biochemical results from measurement at differ- Bristol 1.5 Carlisle
ent laboratories. This is an issue for any multi-centre study, such as Gloucester 0.3 Sunderland
the Renal Registry, which compares biochemical data. Calculating and Leeds (St. James) 1.5 Middlesborough
adjusting for this variation is especially important where centres are Leicester 1.4 St Mary’s London
trying to achieve a percentage of patients meeting a specified “stan- Plymouth 0.5 Oxford
dard.” Variation in laboratory measurement results not only from Sheffield 1.4 Truro
using differing analytical techniques, but also from differing calibration B’ham (Heartlands) 0.5 Di Proton systems:
materials and protocols. Although there have been many multi-centre Nottingham 0.9 Preston
studies published, for example using cholesterol and glycosylated hae- Stevenage 0.6 Swansea
moglobin data, we are unaware of any published paper that makes Hull 0.7 Wrexham
adjustment for inter-laboratory variation. The Renal Registry in con- Total 9.2
junction with the Association of Clinical Biochemists is investigating Scotland 5.0
methods to ‘harmonise’ the data, permitting direct laboratory compari-
son. This is being undertaken through the resources of the national
biochemistry quality assurance scheme NEQAS. Adjustments are re-
quired for albumin, calcium, corrected calcium, phosphate, bicarbon-
ate, cholesterol, glycosylated haemoglobin, ferritin, cyclosporin, creati- By March 1998 we estimate we will cover over 22 million (40%) of
nine and urea. the UK population. The Renal Registry validation software has been
rewritten to make it more robust. Files may be transmitted and received
by modem or via a direct hospital network link over the NHS net.
The first full annual report of the UK Renal Registry will be published
in July 1998. To facilitate their clients joining the registry Clinical
Computing Ltd are now actively co-operating with us. They have sup-
plied the Renal Registry with a copy of their Di-Proton system, and
we are working on making this ‘Registry compatible.’ This will allow
units to join the Renal Registry if they are purchasing new systems or
upgrading their current version of Di-Proton. A further £60,000 has
been received from the Department of Health. Industry has also pro-
vided additional support. The Renal Registry is within budget at the
planned £10 per patient. It is financially secure for the next 12 months.
The Renal Registry has agreed to hold the medical staffing database
for the Renal Association. It is also co-operating with the DoH in a
further renal review and a retrospective study on changes in outcomes
over 10 years for patients in ESRF. The Registry is fully operational
and ready to fulfil its function of Research and Audit in renal failure.
If you would like your unit to join please contact David Ansell.
Reduction of left ventricular mass index with blood pressure reduction
in chronic renal failure. B. Tucker, F. Fabbian1, M. Giles, A. Johnston
and L.R.I. Baker, St. Bartholomew’s Hospital, London, UK and St
Anna Hospital1, Ferrara, Italy. We have reported previously (Nephrol
Dial Transplant 1997;12:724–728) that in non-diabetic chronic renal
failure (CRF) patients, independent risk factors for left ventricular
hypertrophy (LVH), determined echocardiographically, are hyperten-
sion, male sex, body mass index (BMI) and anaemia. We now report
follow up ambulatory blood pressure (ABP) and echocardiographic
findings in 65 patients (26 M, age 51 6 12 years) 24 (11–39) months
after the initial study in order to define the effect of BP control on
left ventricular mass index (LVMI). BMI, serum creatinine (SCr),
creatinine clearance (CrCl), 24 hr urinary protein and sodium, haemo-
globin, fasting cholesterol (Chol), triglycerides, albumin, calcium (Ca),
phosphate and parathyroid hormone (PTH) concentrations were mea-
sured in all patients. There was a significant increase in SCr from 228 6
146 to 280 6 212 mmol/l (p , 0.01) and a reduction in CrCl from 48 6
29 to 44 6 31 (p , 0.03). Chol (p , 0.001) and PTH (p , 0.04)
diminished and Ca (p , 0.02) rose. There was a reduction in mean
nocturnal systolic (p , 0.01) and diastolic (p , 0.01) BP dip. No
significant change in any of the other values occured over the period
of the study. Multiple regression analysis of the change in LVMI asThe above graphs are examples of uncorrected data. At the upper
the dependent variable and change in other parameters as independentrange of albumin, there is a suprisingly close similarity of data between
variables showed a significant association between change in LVMIcentres. At the lower range of albumin values a non-linear correction
and change in ABP only. ACE inhibitor treated patients appeared tofactor is required and this may account for the divergence of lines in
do particularly well. We have been able to isolate the effect of BPthe graph. For many of the biochemical parameters measured, there
upon LVMI, uncomplicated by other potential confounding factorsis a linear correction factor which may be applied.
such as anaemia and volume overload, and have demonstrated for the
first time in CRF patients reduction in LVMI with good BP control.
Levels of BP lower than those hitherto considered satisfactory areRenal Registry Progress March 1998. Additional sites are joining the
Renal Registry. The current situation is: required for reduction in LVMI to occur.
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Outcome of renal replacement therapy in ANCA-associated systemic had no effect. Optimisation of early graft function and prevention of
rejection episodes will improve patient survival; patients with poor graftvasculitis. A. Allen, C. Pusey and G. Gaskin, Renal Section, Division of
Medicine, Imperial College School of Medicine, Hammersmith Hospital, function should be targeted for more intensive treatment to prevent
cardiovascular disease.Du Cane Road, London, UK. ANCA-associated systemic vasculitis
(AASV) commonly leads to end-stage renal disease (ESRD) requiring
renal replacement therapy (RRT). Because of its systemic nature,
potentially fatal extra-renal relapses can occur in patients receiving Chronic renal insufficiency: unmet need for referral to a renal physician.
J. Dautlich, D. Worth1 and J. Strang1, Department of Public Health,dialysis, and those receiving renal allografts can also experience recur-
rent disease within the graft. Accordingly, there has been concern that North Yorkshire Health Authority, York, UK and York District hospi-
tal1, York, UK. The Renal Purchasing Guidelines published by theAASV patients have a poorer outcome on RRT than those with ESRD
of other aetiologies. We addressed this issue by conducting a retrospec- Department of Health in 1996 stressed the value of appropriate and
timely referral to a renal physician for people with chronic renal insuf-tive analysis of 59 AASV patients treated at our unit between 1974
and 1997 who received long-term RRT. We examined patient survival, ficiency. We report the results of a study which sought to quantify the
unmet need for referral to a renal physician. The database of thetransplant survival and the rate of relapse of vasculitis. The diagnosis
was Wegener’s granulomatosis (WG) in 23, microscopic polyangiitis Chemical Pathology Department was used to identify patients who
had a creatinine of greater than 300 micromols/litre, between January(MP) in 33 (10 with renal-limited disease) and Churg-Strauss syndrome
(CSS) in 3. The median ages at diagnosis and commencement of RRT and December 1996. Patients with acute renal failure (creatinine subse-
quently falling to ,300 consistently) were excluded, as were patientswere 52 years and 54 years respectively. Overall, median survival from
initiation of RRT was 107 months (range 2–182), with actuarial survival already known to a renal physician. A questionnaire was completed
by the general practitioner or consultant responsible for the patientat 1 and 5 years 82% and 59% respectively. Unsurprisingly, transplant
recipients were younger and enjoyed a better prognosis: or by audit staff. Using standardised criteria, patients were categorised
as “appropriate” for consideration of dialysis or “inappropriate.” Dial-
ysis was considered to have been inappropriate or irrelevant in the
following situations: those who had died before the study was under-% patient survival
Median age at taken from unrelated causes where renal impairment was not severe
RRT modality ESRD (range) 1 year 5 year enough to warrant dialysis, patients with terminal malignancy, terminal
cardiac or respiratory failure or dementia. A total of 139 patients withDialysis only 61 (26–79) 74 40
chronic renal insufficiency were identified of whom 121 had died atDialysis and transplant 38 (13–65) 100 84
the time of the study.
Relapses occurred in nine patients, 11 during dialysis and 2 in transplant
recipients. Importantly, three fatal relapses were initially misdiagnosed Inappropriate Appropriate
as dialysis complications. Recurrent necrotizing glomerulonephritis led Responsible doctor for dialysis for dialysis Total
to graft loss in one patient. Relapses were 4.5 times commoner in those
Consultant 107 (86%) 18 (14%) 125 (100%)receiving dialysis alone than in those who received transplants. Only
General practitioner 10 (71%) 4 (29%) 14 (100%)three patients died with functioning grafts, but 18 died on dialysis. The
Total 117 (84%) 22 (16%) 139 (100%)overall causes of death included pneumonia (6), heart failure (4),
vasculitis (3) and discontinuation of dialysis (3). Median age at death
was 67 years (range 28–79). 24 transplants were performed in 22 pa-
Of the 22 patients who were considered appropriate for referral, 19tients; graft survival at 1 and 5 years was 86% and 69% respectively.
(86%) were 75 years or older. The under-referral of nearly one inCauses of graft loss were acute and chronic rejection (2 each), recurrent
seven patients with chronic renal insufficiency, most of whom werevasculitis (1) and renal artery thrombosis (1). These data demonstrate
elderly, is of concern. Renal physicians need to ensure that local consul-that AASV patients with ESRD can enjoy good long-term survival,
tants and general practitioners do not deny their patients the benefitparticularly after transplantation, but relapses may still occur. The
of a specialist opinion on the basis of age.sometimes fatal nature of relapses suggests that continuing specialist
follow-up after ESRD is warranted.
Attitudes of physicians to the prevention and treatment of renal insuf-
ficiency. J. Dautlich, J. Strang, and D. Worth1, Department of PublicEarly allograft function and patient survival following renal trans-
Health Medicine, North Yorkshire Health Authority, York, UK andplantation. Y.M. Woo, A.G. Jardine, M.S. McGregor, J.D. Briggs, S.G.
York District Hospital1, York, UK. The Renal Purchasing GuidelinesMacpherson, B.J.R. Junor, M.A. McMillan and R.S.C. Rodger, Renal
published in 1996 stressed the importance of the effective managementUnit, Western Infirmary, Glasgow, United Kingdom. Little is known
of patients with chronic renal insufficiency to slow the decline in renalabout the role of renal allograft function or acute rejection on patient
function and to address co-morbid conditions. We report the resultssurvival post-transplantation. This study was performed to investigate
of a questionnaire sent to all dialysis units in England and to a randomthe effect of patient characteristics and early graft function on long-
sample of general practitioners, general physicians and elderly careterm patient survival. We performed a retrospective analysis of 589
physicians in the Northern and Yorkshire Region. Participants wereadult patients who had first cadaveric kidney transplants between 1984
asked to indicate whether they agreed, disagreed or were unsure aboutand 1993 in a single centre and received Cyclosporin based immunosup-
each of five statements concerning the prevention and treatment ofpression. Median follow-up time was seven years with a range of four
renal insufficiency. Replies were received from 126 renal physiciansto nine years. Kaplan-Meier survival analysis and Cox multivariate
representing 70 (80%) dialysis units, from 146 (63%) general prac-analysis were performed to identify factors that influence patient out-
titioners, 119 (79%) general physicians and 76 (80%) elderly carecome. Of the 589 patients, 168 have since died; 52% of definite cardio-
physicians.vascular causes. Increasing age (p , 0.001) and diabetes (p , 0.001)
There is a significant difference in the views of participating disciplineswere the strongest predictors of poor patient survival. Primary non-
with respect to four out of five of the above statements. If clinicalfunction (PNF) of graft at time of transplantation (p 5 0.002), episodes
behaviour were to reflect the views expressed, this could lead to inap-of acute rejection (AR; p , 0.001) and poor graft function as defined
propriate delay in the referral of patients with chronic renal insuffi-by serum creatinine . 200 umol/L at three months post-transplantation
ciency. In order to strengthen the role of renal physicians in preventing(p 5 0.002) were also associated with patient mortality. Sex, duration
and treating renal insufficiency, integrated evidence based guidelinesof pre-transplant dialysis and delayed graft function (DGF) post-trans-
need to be developed and implemented involving all key medicalplantation did not have significant influence on patient survival. In our
disciplines. It is particularly important to ensure that the criteria forcentre poor renal allograft function in the early post-transplant period
referral to a renal physician are agreed locally. The consequent in-is associated with reduced patient survival. The main determinants of
poor graft function and mortality were AR and PNF; in contrast DGF creased workload for renal physicians needs to be recognised.
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comorbidity may benefit from this expensive treatment. This places
Level of great burdens on providers and purchasers to provide for both theagreement (%) dialysis and the consequent hospital admissions. Some have questionedChi square
the wisdom of this policy particularly since the annual mortality remainsStatement A* B* C* D* (6df)
high (15–20%). We have reviewed the patients accepted onto our
Referral to a nephrologist is indicated if dialysis programme from 1st April 1991 to 31 March 1996 who diedcreatinine is .300 micromols/l in non-
within one year. Factors such as age, comorbidity, social circumstances,diabetic patients. 99 83 77 66 P50.001
cause of death, renal diagnosis and mode of dialysis are assessed. 698
Microalbuminuria should be assessed patients were accepted, of whom 122 (17.5%) died within a year and
annually in insulin dependent diabetics. 93 93 93 95 P50.439 50 (7.1%) died within three months. 81 were male and 41 female.
A 35-year-old man with insulin depen- Median age was 68 years (min. 18 yrs max. 86 yrs sd 11.55 years).
dent diabetes, blood pressure of 140/90 Cause of death is most commonly Cardiac (25.4%) followed by Un-
and persistent microalbuminuria should known Cause (20.5%), Dialysis Withdrawal (15.6%), Malignancy
be considered for treatment with an ace- (13.9%), Infection (9%), CVA (5.7%), Refused Treatment (2.5%). In
inhibitor. 99 86 91 91 P50.015 45 patients, comorbidity at the start of dialysis was assessed using two
scales. (A) The Renal Association Standards document1 (B) The scaleReferral to a physician is indicated for
described by Khan2. Patients were classified as low, medium and highpoorly controlled hypertension with albu-
risk. We tried to identify from comorbidity scoring whether poor out-minuria (.160/95, on 2 or more drugs). 98 89 88 84 P50.010
come was predictable. We found poor agreement (,50%) betweenReferral to a nephrologist is indicated
scales. 44% of patients who died were classified by scale B as mediumfor persistent undiagnosed proteinuria. 96 67 67 63 P50.001
risk. Age does not predict outcome as 42% of patients were under 65
* A – renal physicians, B – general practitioners, C – consultant physicians, D years. We suggest that it is difficult to use current assessments to
– elderly care physicians. accurately predict outcome for individual patients.
Questionnaire survey on current practice in renal osteodystrophy in
A pilot study to determine prognostic markers and to estimate sample the United Kingdom. D. de Takats, E.V. McCloskey, J. Bernard and
size/accrual rate for a randomised control trial in treatment of IgA J.A. Kanis, Centre for Metabolic Bone Diseases at Sheffield, Royalnephropathy. N.R. Pritchard1, P. Dey2, M. Boulton-Jones3, S. Schmitt4, Hallamshire Hospital, Glossop Road, Sheffield, S10 2JF. A postal ques-J. Feehally5 and D.J. O’Donoghue1, on behalf of the Renal Association
tionnaire with questions on: assessment and treatment of renal osteo-Glomerular Disease Trials Group, 1Hope Hospital, Salford. 2Centre
dystrophy; other skeletal problems; and research, was sent to 80 UKfor Cancer Epidemiology, University of Manchester. 3Glasgow Royal
renal units. Replies were received from 51 units (64%) as follows: 48Infirmary. 4Universitat Heidelberg, Austria. 5Leicester General Hospital.
of 72 NHS adult units (67%); 2 of 5 NHS paediatric units; and 1 of 3IgA Nephropathy (IgAN) is the commonest glomerulonephritis in the
private dialysis facilities. Checks of calcium and alkaline phosphataseU.K. and an important cause of end stage renal disease (ESRD).
are frequent in HD patients such that .85% of HD units check bothDespite this, there are few facts established by randomised controlled
monthly, less than 7% of units wait 3 months between tests and nonetrials in IgAN. The aims of this study were to determine if proteinuria
wait longer, but in CAPD patients tests are less frequent and less(.1 g/day) and hypertension could determine the sub-group of IgAN
regular. The modal frequency of parathyroid hormone (PTH) testingwith progressive disease and to establish if doubling of serum creatinine
is 6 monthly in HD patients and 6–9 monthly in CAPD patients. Aboutwas an adequate surrogate marker for progression to ESRD. IgAN
80% of units check PTH at least annually in both HD and CAPD.patients with proteinuria (.1 g/day) were identified from three centres
Fifty units replied regarding radiological assessment. Of these 30 saidover a seven year period. Outcome measures for all patients, that is
that radiographic skeletal assessment was done ‘as clinically indicated’,doubling of serum creatinine within 3 years and eventual progression
17 units perform routine annual radiographs and 3 units at other fre-to ESRD, were established. Data on 109 patients with proteinuria (.1
g/day) were identified and the outcomes shown in the table below; quencies (one six monthly! One 3 yearly and one 5 yearly.) The pre-
ferred sites were as follows: Hands: 51 units, clavicles: 16, skull: 15,
pelvis: 14, feet: 13. Few bone biopsies are performed in the clinical
management of bone disease in the UK and there is no routine useNo. doubling No. developing
of newer biochemical markers of bone turnover. The use of phosphateN serum creatinine ESRD
binders is generally similar in all patients across all units with calcium
Normotensive 20 0 0 carbonate preparations most favoured but aluminium containing prep-↑BP noted during study 25 5 (20%) 5 (20%)
arations are used in almost half the units for pre-dialysis patients, in↑BP at biopsy 64 14 (22%) 13 (20%)
.50% units for CAPD patients and in .70% of HD units. Information
was also obtained on the use of vitamin D derivatives and on other
skeletal problems. 80% of units expressed a positive attitude towardsTherefore, proteinuria .1 g/day and hypertension do identify the sub-
research but only a few are actively engaged in structured osteodystro-set of IgAN patients with progressive disease and doubling of creatinine
phy research.within three years from presentation provides a good surrogate marker
for progression to ESRD. In order to observe a 50% relative reduction
in ESRD, that is, to detect a difference of 10% between the two groups,
Factors determining biopsy proven chronic allograft nephropathy: awe would require a total sample size of 572 for a study power of 90%
retrospective case control study. I. Dasgupta, C.J. Porter and R.P.at the 5% two sided significance level. With an enrolment of 5 patients
Burden, Renal Unit, Nottingham City Hospital, Nottingham, U.K.per centre per year, we would require 20 centres to recruit for 4 years
Chronic allograft nephropathy is the main cause of late graft failure.to attain a study power of 90% (if patients diagnosed within 3 years
were eligible). From this, it does appear that a U.K. factorial study of Both immunological and non-immunological factors are implicated in
intervention in IgAN is feasible and could establish the utility of fish its causation. Here we have compared the role of some of these factors
oil and renin-angiotensin blockade. in 30 patients who lost their grafts with biopsy proven chronic allograft
nephropathy and a group of 30 control patients with stable allograft
Analysis of patients dying within a year of starting dialysis. G. Walters,
G. Warwick and J. Walls, Dept of Nephrology, Leicester General Hospi-
tal, Leicester, UK. The increase in number of patients receiving dialysis 1 Renal Association Standards document Second edition Nov. 1997
2 Khan et al. Lancet vol. 341: 415–418is largely explained by the acceptance that older people with associated
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function matched for age, sex, race, year of transplantation and creati- United Kingdom. We present the clinical outcomes in our 28 year
experience of live donor kidney transplantation. The clinical and com-nine at 6 months. Results are shown below (ap 5 0.007)
puterised records of all live donor transplants carried out in our institu-
tion between May 1969 and August 1997 were examined. Controls
were selected from cadaveric transplant recipients, matched for yearCases (N 5 30) Controls (N 5 30)
of transplantation, age, sex and number of previous grafts. Whilst
Mean pre-transplantation primary renal disease was not matched, the incidence of diabetes melli-
BP (mm Hg) 140.4/80.763.1/2.2 144.8/83.663.1/1.6 tus or systemic renal disease was not significantly different. 136 patients,
Mean post-transplantation median age 28 (14–66) years, received 138 live donor kidney transplants
BP (mm Hg) 146.5/86.661.6/0.9 144.3/8661.8/5.4 in our unit, of which 17 were regrafts, 3 pre-emptive and 3 spousal
HLA matching transplants. Graft survival was excellent and significantly better than
(favorable:not favorable) 8:22 13:17 the matched cadaveric controls (ap , 0.0001). Patient survival was also
Total ischaemic time (hours) 18.4 61.3 17.861.2 better than the controls (bp 5 0.0056).
Delayed graft function (%) 40 33
Mean serum cyclosporin
(ng/L) 251.9620.1 259.0627.1 Graft survivala Patient survivalb
Mean cyclosporin dose
Graft type 1 year 5 years 10 years 1 year 5 years 10 years(mg/kg/day) 4.8 60.36 4.560.17
Total number of acute Live donor 92.2% 80.2% 78.6% 98.4% 97% 95.1%
rejections 27a 12a Cadaveric 76.6% 48.4% 34.4% 96.0% 87.1% 60.7%
Because we have a particular interest in hypertension we also looked Eight early graft losses (,3 months) in the live donor recipients were
at the number and class of antihypertensives used in each group. The due to acute rejection (6), renal vein thrombosis (1) and technical
average number of antihypertensive used was not different 2.1 6 0.2 problems (1). Serum creatinine was 144 1 79 mmol/l in 100 patients
in the cases compared to 2.2 6 0.2 in the controls. However ACE with functioning live donor grafts at latest follow-up of 7.9 1 6.2
inhibitors were used in 10/30 control subjects compared to only 1/30 years. Live donor kidney transplantation produces excellent long-term
in the cases (p 5 0.009). In conclusion, of the immunological and non- patient and graft survival, even if compared to matched cadaveric
immunological factors compared, the number of early acute rejections grafts. Early graft loss is uncommon, particularly since the advent of
was found to be the only factor significantly related to subsequent cyclosporin. Expansion of the live donor transplant programme in the
biopsy confirmed chronic allograft nephropathy. Use of ACE inhibitors United Kingdom could substantially reduce transplant waiting lists and
to control BP may have a protective effect on renal allograft function. improve patient outcomes.
Occult hypoglycaemia caused by haemodialysis. M.A. Jackson, M.R. Pre- and post-transplant echocardiographic abnormalities are pre-
Holland, J. Nicholas, H. Spencer, D. Forster, I.A. MacDonald, New dictors of survival. G.A. Stewart, E.M. McGregor, J.D. Briggs, B.J.R.
Cross Hospital, Wolverhampton. Hypoglycaemia has rarely been re- Junor and A.G. Jardine, Department of nephrology, Western infirmary,
ported in patients during dialysis but is a theoretical risk when glucose Glasgow, Scotland. Premature cardiovascular (CV) disease is the major
free solutions are used. 21 fit, non-diabetic patients with chronic renal cause of death in renal transplant (Tx) recipients. We have previously
failure were haemodialysed using a glucose free dialysis solution. They shown that pre-tx echocardiographic (echo) abnormalities, specifically
were asked not to eat during the first hour on haemodialysis. Blood increased ventricular end diastolic dimensions (EDD) and increased
was sampled at regular intervals during the first hour of dialysis for left ventricular mass index (LVMI), are strong predictors of post trans-
glucose, noradrenaline, adrenaline, insulin, glucagon and cortisol. Dial- plant CV mortality. However, little is known about changes in echo
ysate fluid was sampled for glucose, noradrenaline and adrenaline. parameters post-tx and their prognostic relevance. We performed a
Plasma glucose fell below 4 mmol/l in 9 of the 21 patients, below 3.5 survival analysis of 78 patients who had an echo immediately prior to
mmol/l in 6 and below 3.0 mmol/l in 3 patients. The lowest recorded renal tx between 1988 and 1991 and again one year later. All patients
value was 2.1 mmol/l. Mode glucose loss in the waste dialysis fluid was had functioning renal allografts at one year; 16 have since died. Patients
6 g/hr. The patients had no symptoms of hypoglycaemia. There was who died had greater post-tx LVMI (169 [103, 273] vs. 132 [62, 370]
no significant difference in the mean insulin, cortisol, glucagon, or g/m, median [range], deceased vs. survivors, p 5 0.05); pre-tx LVMI
adrenaline levels between the euglycaemic (plasma glucose above 4.0 was not different-median 147 vs. 142 (p 5 0.34). In contrast, pre-tx
mmol/l) and the hypoglycaemic groups. Mean noradenaline 4.65 chamber diameters were greater in those who died, (e.g. EDD: 5.7
nmol/l (normal basal level 0.5 – 3.5 nmol/l) and glucagon 169 ng/l [4.1, 7.5] vs. 5.1 [3.0, 7.3] cm, p 5 0.01); post-tx diameters were not
(normal range 50 – 150 ng/l) concentrations were slightly elevated in different. In a survival analysis, age at tx was the strongest determinant
both groups. The average noradrenaline loss for euglycaemic patients of outcome (p 5 0.01), followed by pre-tx EDD (p 5 0.02) and improve-
was 31.8 nmol/h (range 13.4–71) compared with hypoglycaemic patients ment in EDD post-tx (p 5 0.07). Subdivision of patients by the median
of 44.8 (range 2.5–61.7, P 5 0.772) and for adrenaline it was 3.3 nmol/ pre-tx EDD or post-tx LVMI were associated with survival in a Kaplan-
h (range 0.45–8.5) for euglycaemic patients and 2.0 (range 0.75–3.6, Meier analysis (p 5 0.04 LVMI, 0.02 EDD, log rank test). These data
P 5 0.244) for the hypoglycaemic group. When 7 patients from this confirm the clinical importance of echocardiography in renal trans-
group were subsequently dialysed with a dialysis fluid containing 5.5 plantation, and identify potential therapeutic targets to reduce CV
mmol of glucose their plasma glucose became stabilised within the mortality. Novel strategies are urgently required to: (1) reduce pre-tx
normal range throughout haemodialysis. Hypoglycaemia can occur ventricular dilatation (EDD), (2) improve reduction of chamber size
during dialysis with glucose free solutions and further research is re- following transplantation and (3) regress left ventricular hypertrophy
quired to assess its significance. in transplant recipients.
Long-term outcomes after live donor kidney transplantation. M.S. Results of endovascular intervention on blood pressure and renal func-
MacGregor1, A.M. Akyol2, D.N.H. Hamilton1, K.F. Kyle1, S.G. Mac- tion in atherosclerotic renovascular disease. K. Bel’eed, M. Wright, A.
pherson1 and M.A. Watson1, 1Renal Transplant Unit, Western Infirmary, Nicholson1, D. Eadington, M. Farr and L. Sellars, Departments of Renal
Glasgow, G11 6NT, Scotland. 2Department of Surgery, Royal Infirmary, Medicine, and Vascular Radiology1, Hull Royal Infirmary, Hull, UK.
Edinburgh, EH3 9YW, Scotland. Transplantation is considered the We reviewed our experience with percutaneous renal artery angi-
optimum treatment for end-stage renal disease, but is limited by the oplasty (PTRA) 6 stenting in 51 patients (36 M, 15 F; mean age 66
supply of organs. Expansion of live donor transplantation could amelio- (36–80) years with ARAS. All patients were receiving antihypertensive
therapy (mean 2.7 6 1 agents, mean SBP 180 6 25 mm Hg, meanrate this shortage, but is still only used to a limited degree in the
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DBP 94 6 12 mm Hg). Serum creatinine (SCr) was ,120 mmol/l (n 5 (Cit) by nitric oxide synthase but can also be metabolised to ornithine
(Orn) by arginase. We studied possible alterations in these pathways8), 120–400 mmol/l (n 5 31), and .400 mmol/l (n 5 12). The contralat-
eral renal artery (RA) was occluded in 20 patients, and 3 patients had in uraemic human microvascular endothelial cells (HMEC*). Cells
were cultured in medium with 10% uraemic (Ur) or control (Con)a single kidney. The RA lesions were ostial in 29 and distal in 22
patients. Twenty three arteries had PTRA only, while 33 stents were human plasma for 48 hr. following which supernatant was replaced
with fresh medium alone for 30 min (incubation A). For incubationplaced in 30 arteries (technical success rate 77% and 92% respectively).
Indications for stenting were; ostial lesion (25), previous PTRA (3), B, following the above, fresh medium containing 2 mM bradykinin
(BK; eNOS agonist) was substituted for a further 10 min. After bothimmediate recoil (1), and RA dissection (1). Patients were followed
up for mean of 27 (1–144) months. Results were as follows: incubations cells and supernatants were assayed for Arg, Orn and Cit
by HPLC. Results are expressed as mean 6 standard deviation (mmol/
L). Incubation A: [Arg] was higher and [Orn] lower in Ur supernatants
compared to Con (Arg: Ur, 318 6 9; Con, 84 6 112: p , 0.02; Orn:SCr (lmol /l )
Ur, 17 6 12; Con, 57 6 14; p , 0.01). Intracellular [Arg] and [Orn]
,120 120–400 .400 followed a similar pattern (Arg: Ur, 3.7 6 0.5; Con, 1.6 6 0.5: p ,
(N 5 8) (N 5 31*) (N 5 12) 0.005 ; Orn: Ur, 8.6 6 12; Con, 42 6 9: p 5 0.001). Cit was not present
in either Ur or Con supernatants or cells. Incubation B: [Arg] wasUni/bilateral disease 6/2 9/22 5/7
greater but [Orn] similar in Ur supernatants compared to Con (Arg:BP (%)
Ur, 371 6 97; Con, 20 6 8: p , 0.001; Orn: Ur, 36 6 9; Con, 42 6cured 0 (0) 0 (0) 0 (0)
35: p 5 NS). Intracellular [Arg] and [Orn] followed a similar patternimproved 4 (50) 18 (60) 7 (58)
(Arg: Ur, 3.7 6 1; Con, 0.3 6 0.3: p , 0.005; Orn: Ur, 30 6 5; Con,not improved 4 (50) 12 (40) 5 (52)
42 6 42: p 5 NS). Cit was present in Ur supernatants only (Ur,SCr (%)
2.1 6 2). These results indicate reduced arginase activity in uraemicimproved 0 (0) 4 (13) 1 (8)
endothelial cells which is overcome by the presence of BK. The re-stable 7 (88) 15 (50) 1 (8)
sulting higher [Arg] may be responsible for increase NO release.worse 1 (13) 11 (37) 10 (84)
*Human microvascular endothelial cells (HMEC) (gift from Drs Ades,
* One patient died at home 10 days after intervention Candal and Lawley)
We conclude that PTRA 6 stenting improves BP control in ,50% of
Gelatinase activity in vivo is not decreased in human glomerular dis-patients with ARAS, regardless of renal function. The procedure can
ease. M.E. Thomas, G. Barker, P.N. Furness1 and K.P.G. Harris, Renalimprove or stabilise renal function in patients with SCr , 400 mmol/l,
Unit, Leicester General Hospital, and Dept. of Pathology1, Universitybut is largely ineffective if SCr . 400 mmol/l. A randomized study is
of Leicester Medical School. Interstitial fibrosis is due to increasedrequired to determine whether intervention in appropriately selected
matrix production and/or reduced matrix degradation. Matrix metallo-patients with progressive renal impairment can delay the onset of
proteinases (MMPs) play an important role in matrix degradation.ESRF.
These include the type IV collagenases (MMPs-2 and -9, also called
gelatinase A and B). Animal studies have suggested that reduced
matrix degradation is an important cause of interstitial fibrosis. InMeasurement of chronic damage in renal biopsy specimens. M.A.S.
order to quantify gelatinase activity, we developed a method knownFerreira and A.J. Howie, Department of Pathology, University of Bir-
as in situ zymography for use in human renal biopsies. Sections weremingham, UK. Few methods have been described of objective measure-
coated with a gelatin containing autoradiographic emulsion. Gelatinasement of chronic damage in renal biopsy specimens, which is likely to
activity degrades the emulsion during incubation, and on developingbe an important prognostic feature. An interactive image analysis
activity is seen as white areas on a black background. This was quanti-system was used to outline areas of chronic damage on images of
fied by image analysis, using NIH Image. The following biopsies werecortex stained by periodic acid—methenamine silver. Chronic damage
studied: controls (patients with microhaematuria but a normal renalwas recognised by tubular atrophy including thyroidisation, interstitial
biopsy); focal glomerulosclerosis (FSGS); minimal change nephropa-fibrosis and global sclerosis of glomeruli. Amount of damage was
thy; and membranous glomerulonephritis. Cortical gelatinase activityexpressed as percentage of cortical area. Four groups were studied:
(per unit area on an arbitrary scale, mean 6 SD shown) was as follows:IgA nephropathy (54 biopsies, 48 with 10.5 years median follow up);
Henoch—Schoenlein nephritis (45 biopsies, 44 with 4 years median
follow up); renal allografts (14 biopsies, 11 with 7 years median follow
up); and others (50 biopsies, 31 with 7 years median follow up). The Creatinine Glomerular
index of chronic damage ranged from 0 to 90% and correlated with (lmol /l ) gelatinase Tubulointerstitial
plasma creatinine at biopsy (r 5 0.50) and plasma creatinine at follow Group N at biopsy activity gelatinase
up (r 5 0.58). The index was a more accurate prognostic feature than
1. Normal controls 9 71 612a,b,c 62.1616.6d 54.9616.1extent of global sclerosis. Of 76 with follow up and an index under
2. GSGS 7 187 6206a 56.3614.7 50.0613.210%, 7 (9%) had renal death, and of 58 with follow up and an index
3. Minimal change 11 107630b 61.8618.0 56.3614.9of at least 10%, 39 (67%) had renal death (sensitivity 85%, specificity
4. Membranous GN 9 190 6138c 85.8620.9d 65.7613.378%). No extent of global sclerosis had this sensitivity and specificity as
a predictor of long term outcome. Immunostaining of biopsy specimens Mann Whitney tests a.b,c P , 0.02; dP 5 0.04
with an antibody to collagen type 3 allowed automatic image analysis
of the extent of staining. This correlated with the index of chronic
There was no evidence of reduced gelatinase activity in the groupsdamage (r 5 0.47) but did not have the same sensitivity and specificity
with glomerular disease. On the contrary, glomeruli in membranousas a predictor of outcome. Measurement of chronic damage by the
glomerulonephritis showed significantly increased gelatinase activity.method we describe was straightforward and easy, and gave results of
These data strongly suggest that reduced MMP-2 or -9 activity doesprognostic significance.
not contribute to the pathogenesis of interstitial fibrosis in human
glomerular disease.
Reduced arginase activity results in increased intracellular arginine in
uraemic endothelial cells. R.C. Thuraisingham, N.B. Roberts1, A.C.
Polymorphisms within Interleukin 4 and the Interleukin 4 receptorMendes Ribeiro2 and M.M. Yaqoob, Dept. Nephrology, Royal Hospitals
in Minimal Change Nephropathy. R.G. Parry1, K.M. Gillespie1, A.P.Trust, London, Dept. Chemical Pathology, Royal Liverpool University
Parnham1, G. Clark2 and P.W. Mathieson1, Academic Renal Unit, South-Hospitals1 and Dept. of Physiology, Oxford University2. Our previous
mead Hospital, Bristol1, Guy’s Hospital, London2. Minimal Changestudies demonstrated increased basal nitric oxide (NO) release from
uraemic endothelial cells. Arginine (Arg) is converted to L-citrulline Nephropathy (MCN) is associated with atopy and increased serum
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interleukin 4 (IL-4) levels. We have studied the genes for IL-4 and gain of function via enhanced signalling and increased expression of
the IgE receptor CD23. This mutation was more common in patientsIL-4 receptor in MCN. 300bp of the core promoter of the IL-4 gene
was screened for polymorphism by SSCP and sequencing in 36 patients with atopy. We have examined the frequency of this mutation in pa-
tients with MCN. DNA from 91 patients and 47 controls was examined.with MCN and 59 controls. We found no polymorphisms in this regula-
tory region indicating that a gain of function polymorphism in the IL-4 68 patients and 32 controls were homozygous for the wild-type allele,
17 patients and 13 controls were heterozygous and 6 patients and 2promoter is unlikely to underlie enhanced IL-4 levels in MCN. Analysis
of a polymorphic dinucleotide repeat in the second intron of the IL-4 controls were homozygous for the mutant allele. Statistical analysis
revealed no differences between the groups. We have found no evi-gene revealed that there was no difference in allele frequencies between
patients and controls. Recently, it has been shown that a mutation in dence that IL-4 or IL-4 receptor polymorphisms are associated with
MCN.the a subunit of the IL-4 receptor at position 576 is associated with a
